sort code,Generic Name,Brand Name,MOA/Target,"MW (free base/acid, no hydrate)",Dose,Dose Unit,Route,infusion,dose schedule,Cmax (uM),Cmax (mol/liter),Cmax (g/l),Cmax (ng/ml),Cmax (mg/l),Cmax (raw units),Tmax   hr,T1/2        hr,AUC  (raw units),AUC   (ng•hr/ml),Cl,Vd,Protein binding,"Css, ave",Initial U.S. approval,Reference,pubmed link,Reference URL,Drug Product Label URL,Cancer Indication,Notes,unit list,route list
1,Abarelix,Plenaxis,GnRH antagonist,1416,100,mg,IM,-,q 2 wk X2; q 4 wk,0.031,3.06E-08,0.0000434,43.4,0.0434,43.4 ng/ml,72,316.8,500 ng•day/ml,12000,208 L/day,4040 L,96-99%,,2003,Drug Product Label,n/a,http://www.accessdata.fda.gov/drugsatfda_docs/label/2003/21320_plenaxis_lbl.pdf,http://www.accessdata.fda.gov/drugsatfda_docs/label/2003/21320_plenaxis_lbl.pdf,Prostate ,Only physicians who have enrolled in the Plenaxis™ User Safety Program may prescribe Plenaxis™,,
4,Afatinib,Gilotrif,"Kinase inhibitor (Tyrosine): EGFR, HER2, HER4",486,40,mg,PO,-,qd,0.052,5.19E-08,0.0000252,25,0.025,25.2 ng/ml,4,26.9,324 ng•hr/ml,324,952 ml/min,2220 L,95%,,2013,"Clin Pharmacokinet 2013, 52(12):1101-9",http://www.ncbi.nlm.nih.gov/pubmed/23813493,http://link.springer.com/article/10.1007%2Fs40262-013-0091-4,https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Afatinib,Lung (NSCLC):  non-small cell lung cancer (metastatic) with EGFR exon 19 deletions or exon 21 (L858R) substitution mutations,"irreversible inhibitor.  FDA approved afatinib (Gilotrif tablets, Boehringer Ingelheim Pharmaceuticals, Inc.), for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations as detected by an FDA-approved test.  The safety and efficacy of afatinib have not been established in patients whose tumors have other EGFR mutations.  Concurrent with this action, FDA approved the therascreen EGFR RGQ PCR Kit (QIAGEN) for detection of EGFR exon 19 deletions or exon 21 (L858R) substitution mutations.  July 12, 2013 More Information: http://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm360574.htm",mg/m2,Intra Cisternal
5,Alectinib ,Alecensa,"Kinase inhibitor (Tyrosine): ALK, RET",483,600,mg,PO,-,BID,1.38,1.38E-06,0.000665,665,0.67,665 ng/ml,4,33,7430  ng•hr/ml,7430,81.9 L/h,4016 L,>99%,,2015,Drug Product Label,n/a,http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/208434s000lbl.pdf,https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Alectinib,"Lung (NSCLC):  non-small cell lung cancer (metastatic), ALK-positive",,mg/kg/day,
6,Alfuzosin  ,UroXatral,Alpha1 Antagonist,389,10,mg,PO,-,qd,0.035,3.49E-08,0.0000136,14,0.014,13.6 ng/ml,8,10,194 ng•hr/ml,194,-,3.2 L/kg,82-90%,,2003,Drug Product Label,n/a,http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/021287s017lbl.pdf,https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Alfuzosin,not approved for cancer indications.  Prostate: benign prostatic hyperplasia,not approved for cancer indications: indicated for the treatment of signs and symptoms of benign prostatic hyperplasia,mg/kg,IV
7,Allopurinol,Zyloprim,Nucleoside/Antimetab: Xanthine Oxidase Inhibitor,136,300,mg,PO,-,qd,14.3,1.43E-05,0.00194,1940,1.9,1936 ng/ml,1.4,1.4,4814 ng•hr/ml,4814,-,-,negligible,,1966,"J Clin Pharm Ther 2001, 26(2): 113",http://www.ncbi.nlm.nih.gov/pubmed/11350534,http://onlinelibrary.wiley.com/doi/10.1046/j.1365-2710.2001.00329.x/epdf,https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Allopurinol,"Leukemia, lymphoma and malignancies: management of patients who are receiving cancer therapy which causes elevations of serum and urinary uric acid levels.","xanthine oxidase inhibitor indicated for management of patients with leukemia, lymphoma and malignancies who are receiving cancer therapy which causes elevations of serum and urinary uric acid levels.  Active metabolite oxipurinol (alloxanthine),  also is an inhibitor of xanthine oxidase, with Cmax of 6.5 ug/ml and T1/2 of 15 hours.",units/m2,PO
8,Altretamine,Hexalen,Alkylating/DNA damage,210,200,mg,PO,-,-,3.76,3.76E-06,0.00079,790,0.79,790 ng/ml,0.5-3,4.7- 10.2,-,-,-,-,94%,,1990,Pharm Weekbl Sci 1989; 11:218-223,http://www.ncbi.nlm.nih.gov/pubmed/2515524,http://link.springer.com/article/10.1007/BF01959414,https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Altretamine,Ovarian:  following first-line therapy with a cisplatin and/or alkylating agent-based combination.,Cmax varies widely with formulation; Hexalen @ 200 mg po gave 277 ng/ml,,IM
9,Amifostine,Ethyol,Chemoprotective: ROS Scavenger,214,200,mg/m2,IV,7.5 min,-,105,1.05E-04,0.022471678,22472,22,104.9 umol/L,-,0.26,1187 umol•min/L,4238,1.48 L/min,-,negligible,,1995,"J Clin Pharmacol 2002, 42(2): 166",http://www.ncbi.nlm.nih.gov/pubmed/11831539,http://onlinelibrary.wiley.com/doi/10.1177/00912700222011201/abstract;jsessionid=E3477B211E5A7D1158278B2FFD2A0F55.f03t01,https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Amifostine,Ovarian: reduce the cumulative renal toxicity associated with repeated administration of cisplatin in patients with advanced ovarian cancer.,Indicated to reduce the cumulative renal toxicity associated with repeated administration of cisplatin in patients with advanced ovarian cancer.  Less than 10% of parent remains in the plasma 6 minutes after drug administration. Parent is rapidly metabolized by alkaline phosphatase to an active free thiol metabolite (WR-1065).,,
10,Aminoglutethimide,Cytadren,Steroid metabolism: Pregnenolone synthesis inhibitor (P450scc; CYP11A1),232,500,mg,PO,-,-,25.4,2.54E-05,0.0059,5900,5.9,5.9 ug/ml,1.5,12.5,-,-,-,-,21-25%,,1980,Drug Product Label,n/a,http://www.accessdata.fda.gov/drugsatfda_docs/label/2003/018202s021lbl.pdf,http://www.accessdata.fda.gov/drugsatfda_docs/label/2003/018202s021lbl.pdf,not approved for cancer indications; approved for Cushing's syndrome,not approved for cancer indications.  Discontinued,,
11,Aminolevulinic Acid  ,Levulan Kerastick,Photosensitizer,131,100,mg,IV*,1 min,-,129,1.29E-04,0.0169,16900,17,16.9 ug/ml,-,0.83,13.7 ug•hr/ml,13700,7.8 L/h,9.3 L,-,,1999,"J Pharmacol Exp Ther 2002, 301(2): 507",http://www.ncbi.nlm.nih.gov/pubmed/11961050,http://jpet.aspetjournals.org/content/301/2/507.full.pdf+html,https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Aminolevulinic,Actinic Keratosis of the face or scalp (Topical),"Approved only for topical administration, used in conjunction with photodynamic illumination; systemic exposure is undetectable following topical administration.  For bladder cancer, intravesiclular delivery of a dose of 1.33 grams gave 5.35 mg/ml urine, diluted by urine from target concentration of 24 mg/ml.  Oral admin: 100 mg p.o. gave Cmax of 4.6 ug/ml.",,
12,Anastrozole  ,Arimidex ,Steroid metabolism: Aromatase Inhibitor,293,1,mg,PO,-,qd,0.035,3.48E-08,0.0000102,10,0.01,10.2 ng/ml,-,41.3,536 ng•hr/ml,536,-,-,40%,,1995,"J Pharm Biomed Anal 2008, 48(3): 853",http://www.ncbi.nlm.nih.gov/pubmed/18657375,http://www.sciencedirect.com/science/article/pii/S0731708508003518,https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Anastrozole,Breast:   locally advanced or metastatic;   hormone receptor-positive early breast cancer.,"Anastrozole mean steady-state minimum plasma concentrations in Caucasian and Japanese postmenopausal women who received 1 mg of anastrozole daily for 16 days were 25.7 and 30.4 ng/mL, respectively.",,
13,Arsenic Trioxide  ,Trisenox ,not defined; Apoptosis Inducer,198,0.1,mg/kg,IV,2 h,-,0.91,9.10E-07,0.00018,180,0.18,0.18 ug/ml,-,-,see notes,see notes,-,562 L,75%,,2000,"Blood 2001, 98(2): 266-271;  also see Blood 1996, 88(3): 1052; and Drug Product Label",http://www.ncbi.nlm.nih.gov/pubmed/11435292,http://www.bloodjournal.org/content/98/2/266.long?sso-checked=true,https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Trisenox,"Leukemia: acute promyelocytic leukemia (APL) refractory to  retinoid and anthracycline chemotherapy, and whose APL is characterized by the presence of the t(15;17) translocation or PML/RAR-alpha gene expression.","Immediately hydrolyzed to arsenious acid (AsIII)., the pharmacologically active species of arsenic trioxide.  Following once daily doses of 0.15 mg/k, the daily exposure to AsIII (mean AUC0-24) was 194 ng·hr/mL (n=5) on Day 1 of Cycle 1 and 332 ng·hr/mL (n=6) on Day 25 of Cycle 1, which represents an approximate 2-fold accumulation.",,
14,Axitinib,Inlyta,"Kinase inhibitor (Tyrosine): VEGFR, PDGFR",386,5,mg,PO,-,BID,0.163,1.63E-07,0.000063,63,0.063,63 ng/ml,1.8,3.1,466 ng•hr/ml,466,43 L/h,182 L,>99%,,2012,"J Clin Oncol 2005, 23(24): 5474",http://www.ncbi.nlm.nih.gov/pubmed/16027439,http://jco.ascopubs.org/content/23/24/5474.long,https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Axitinib,Kidney: renal cell carcinoma (RCC) after failure of one prior systemic therapy, data reported following 29 days of dosing,,
15,Azacitidine  ,Vidaza,Nucleoside/Antimetab: DNA Methyltransferase (DNMT) Inhibitor;  demethylating agent,244,75,mg/m2,SC,-,qd X 7,3.07,3.07E-06,0.00075,750,0.75,750 ng/ml,0.5,0.68,960 ng•hr/ml,960,167 L/h,76 L,-,0.000038495,2004,"Drug Product Label; FDA NDA 50-794 Clinical Pharmacology and Biopharmaceutics Review; see also J Clin Pharmacol 2005, 45(5): 597",http://www.ncbi.nlm.nih.gov/pubmed/15831784,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/50-794_Vidaza_BioPharmr.pdf,https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Azacitidine,"Myelodysplastic Syndromes (MDS):  French-American-British (FAB) myelodysplastic syndrome subtypes: refractory anemia (RA) or refractory anemia with ringed sideroblasts (if accompanied by neutropenia or thrombocytopenia or requiring transfusions), refractory anemia with excess blasts (RAEB), refractory anemia with excess blasts in transformation (RAEB-T), and chronic myelomonocytic leukemia (CMMoL).",IV Cmax was 2750 ng/ml;  AUC similar to SC; F= 89%,,
16,Azacitidine  ,Vidaza,Nucleoside/Antimetab: DNA Methyltransferase (DNMT) Inhibitor;  demethylating agent,244,75,mg/m2,IV,10-40 min,qd X 7,11.3,1.13E-05,0.00275,2750,2.8,2750 ng/ml,-,0.36,1044 ng•hr/ml,1044,146 L/h,76 L,-,0.000038495,2004,"Drug Product Label; FDA NDA 50-794 Clinical Pharmacology and Biopharmaceutics Review; see also J Clin Pharmacol 2005, 45(5): 597",http://www.ncbi.nlm.nih.gov/pubmed/15831784,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/50-794_Vidaza_BioPharmr.pdf,https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Azacitidine,"Myelodysplastic Syndromes (MDS):  French-American-British (FAB) myelodysplastic syndrome subtypes: refractory anemia (RA) or refractory anemia with ringed sideroblasts (if accompanied by neutropenia or thrombocytopenia or requiring transfusions), refractory anemia with excess blasts (RAEB), refractory anemia with excess blasts in transformation (RAEB-T), and chronic myelomonocytic leukemia (CMMoL).",IV dose,,
17,Belinostat,Beleodaq,HDAC inhibitor,318,1000,mg/m2,IV,30 min,qd X 5 X 3 wk,134,1.34E-04,0.042657,42657,43,42657 ng/ml,-,1,29005 ng•hr/ml,29005,37.6 L/h/m2,16.5 L/m2,94%,,2014,FDA NDA 206256: Clinical Pharmacology and Biopharmaceutics Review,n/a,www.accessdata.fda.gov/drugsatfda_docs/nda/2014/206256Orig1s000ClinPharmR.pdf,https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Belinostat,Lymphoma: peripheral T-cell lymphoma (PTCL): relapsed or refractory,,,
18,Bendamustine   ,Treanda ,Alkylating/DNA damage,358,120,mg/m2,IV, 60 min,-,16.3,1.63E-05,0.00584,5840,5.8,5839 ng/ml,-,0.7,13635 ng•hr/ml,13635,31.7 L/h,40 L,94-96%,,2008,"Cancer Chemother Pharmacol 2010, 66(6): 1039",http://www.ncbi.nlm.nih.gov/pubmed/20140617,http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956859/,https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Bendamustine,Leukemia: Chronic Lymphocytic Leukemia (CLL);  Non-Hodgkin Lymphoma (NHL),,,
19,Bexarotene  ,Targretin ,RXR agonist,348,300,mg/m2,PO,-,-,3.39,3.39E-06,0.00118,1180,1.2,1182 ng/ml,2.5,3.4,5980 ng•hr/ml,5980,-,-,>99%,,1999,"J Clin Oncol 2001, 19(9): 2456",http://www.ncbi.nlm.nih.gov/pubmed/11331325,http://jco.ascopubs.org/content/19/9/2456.long,https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Bexarotene,Lymphoma: cutaneous T-cell lymphoma,,,
20,Bicalutamide,Casodex,Androgen Receptor Antagonist,430,50,mg,PO,-,qd,1.78,1.78E-06,0.000768,768,0.77,0.768 ug/ml,31,139,230838 ug•hr/L,230838,0.32 L/h,-,96%,,1995,"Drug Product Label; AUC from Clin Ther. 2009, 31:3000–3008",http://www.ncbi.nlm.nih.gov/pubmed/20110037,http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/020498s025lbl.pdf,https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Bicalutamide,"Prostate: metastatic carcinoma of the prostate, in combination with a luteinizing hormone-releasing hormone (LHRH) analog for the treatment of Stage D2.",combo with LHRH antagonist,,
21,Bleomycin,Blenoxane,DNA synthesis inhibitor,1416,15,mg/m2,IV,bolus,-,706,7.06E-04,1,1000000,1000,1 mg/mL,-,4,299.5 mg•min/ml,4.99E+06,50.5 ml/min/m2,17.5 L/m2,1%,,1973,"Cancer Chemother. Pharmacol. 1, 177-181 (1978)",http://www.ncbi.nlm.nih.gov/pubmed/86392,http://link.springer.com/article/10.1007/BF00253118,https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Bleomycin,"Squamous Cell Carcinoma (Head and neck);  Lymphomas (Hodgkin's Disease, non-Hodgkin's lymphoma);   Testicular Carcinoma; Malignant Pleural Effusion","value from graphic, estimated to C0; 1 unit = 1 mg ",,
22,Bortezomib  ,Velcade ,Proteosome inhibitor,384,1.3,mg/m2,IV,bolus,2x/wk x 2 wk,0.312,3.12E-07,0.00012,120,0.12,120 ng/ml,0.08,48.7,196 ng•hr/ml,196,25.9 L/h,1465 L,83%,5.29E-06,2003,"Clin Pharmacokin 2009, 48(3): 199",http://www.ncbi.nlm.nih.gov/pubmed/19385713,http://link.springer.com/article/10.2165%2F00003088-200948030-00006,https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Bortezomib,Multiple Myeloma; Mantle Cell Lymphoma,Data are for Day 8,,
23,Bosutinib,Bosulif,"Kinase inhibitor (Tyrosine): BCR-Abl, Src",530,500,mg,PO,-,qd,0.377,3.77E-07,0.0002,200,0.2,200 ng/ml,6-Apr,22.5,3650 ng•hr/ml,3650,189 L/h,6080 L,96%,,2012,Drug Product Label,n/a,http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/203341s003lbl.pdf,https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Bosutinib,"Leukemia: chronic myelogenous leukemia:   chronic, accelerated, or blast phase Philadelphia chromosome-positive (Ph+) CML with resistance or intolerance to prior therapy.",,,
24,Busulfan,Busulflex,Alkylating/DNA damage,246,0.8,mg/kg,IV,2 h,q. 6 h,4.96,4.96E-06,0.001222,1222,1.2,1222 ng/ml,-,-,1167 umol•min/L,4790,2.52 ml/min/kg,0.64 L/kg,32%,8.10E-07,1954,Drug Product Label,n/a,http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/020954s014lbl.pdf,https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Busulfan,Leukemia: chronic myelogenous leukemia:  for use in combination with cyclophosphamide as a conditioning regimen prior to allogeneic hematopoietic progenitor cell transplantation., *protein binding is irreversible,,
25,Cabazitaxel  ,Jevtana ,Tubulin: microtubule stabilizing,836,25,mg/m2,IV,1 h,q. 3 wk,0.27,2.70E-07,0.000226,226,0.23,226 ng/ml,1,95,991 ng•hr/ml,991,48.5 L/h,4864 L,89-92%,,2010,Drug Product Label,n/a,http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/201023s015lbl.pdf,https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Cabazitaxel,Prostate:  in combination with prednisone for the treatment of hormone-refractory metastatic prostate cancer previously treated with a docetaxel-containing treatment regimen.,,,
26,Cabozantinib,Cometriq,"Kinase inhibitor (Tyrosine): c-MET, VEGFR2, RET",502,140,mg,PO,-,qd,4.61,4.61E-06,0.00231,2310,2.3,2310 ng/ml,5-Feb,55,41.6 ug•hr/ml,41600,4.4 L/h,349 L,99.70%,,2012,J Clin Oncol. 2011 Jul 1;29(19):2660-6; Drug Product Label,http://www.ncbi.nlm.nih.gov/pubmed/21606412,http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3646303/,https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Cabozantinib,"Thyroid: medullary thyroid cancer (progressive, metastatic); Kidney: advanced renal cell carcinoma","XL-184; approved 11.30.12 Data are for MTD (175 mg); Recommended dose is 140 mg.  Accumulation of 4-5X (AUC) on repeated dosing.  MTD=175 mg; data given for multiple dosing (day 19);  single dose(175 mg PO) Cmax=544 ng/ml, AUC=7.7 ug.h/ml",,
27,Capecitabine  ,Xeloda ,Nucleoside/Antimetab: Pyrimidine antagonist,359,1250,mg/m2,PO,-,BID,21.1,2.11E-05,0.00757,7570,7.6,7.57 ug/ml,0.82,0.43,507 ug•min/ml,8450,5.55 L/min,217 L,approx 35%,,1998,"Cancer Chemother Pharmacol 2011, 67(3): 613",http://www.ncbi.nlm.nih.gov/pubmed/20495919,http://link.springer.com/article/10.1007%2Fs00280-010-1363-4,https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Capecitabine,"Colon: colorectal Cancer,  Breast Cancer",5-FU prodrug.  Total protein binding of parent and metabolites is less than 60%; parent binding to albumin is approx. 35%,,
28,Carboplatin  ,Paraplatin,Alkylating/DNA damage,371,400,mg/m2,IV,30 min,-,135,1.35E-04,0.05,50000,50,50 ug/ml,0.5,3,4-6 mg•min/ml**,83333,4.4 L/h,16 L,0%,,1989,"Cancer Chemother Pharmacol 1988, 22(3): 263",http://www.ncbi.nlm.nih.gov/pubmed/3044634,http://link.springer.com/article/10.1007/BF00273422,https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Carboplatin,Ovarian: Ovarian Carcinoma,"** AUC given is target AUC for carboplatin as single agent;  parent is not bound to plasma protein, but released platinum binds irreversibly",,
29,Carfilzomib,Kyprolis,Proteosome inhibitor  ,720,27,mg/m2,IV,5 min,-,5.88,5.88E-06,0.004232,4232,4.2,4232 ng/ml,-,< 1,379 ng•hr/ml,379,151-263 L/h,28 L,97%,,2012,Drug Product Label,n/a,http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/202714s009lbl.pdf,https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Carfilzomib,Multiple Myeloma,"ONO-7057, PR-171; approved in USA 07.21.12",,
30,Carmustine  ,BiCNU,Alkylating/DNA damage,214,600,mg/m2,IV,2 h,-,19.4,1.94E-05,0.00415,4150,4.2,4.15 ug/mL,-,-,-,-,-,-,80%,,1977,Clin Cancer Res. 2002 Mar;8(3):698-705.,http://www.ncbi.nlm.nih.gov/pubmed/11895898,http://clincancerres.aacrjournals.org/content/8/3/698.long,https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Carmustine,"Brain:  glioblastoma, brainstem glioma, medulloblastoma, astrocytoma, ependymoma, and metastatic brain tumors; Multiple myeloma, in combination with prednisone;  Hodgkin’s disease (as secondary therapy in combination with other approved drugs);  Non-Hodgkin’s lymphomas (as secondary therapy in combination with other approved drugs)",600 mg/m2: 4.15 mg/L graphically. Recommended dose is 150-200 mg/m2 IV,,
31,Celecoxib,Celebrex,COX-2 inhibitor,381,400,mg,PO,-,BID,4.6,4.60E-06,0.001752,1752,1.8,1752 ng/ml,-,8.8,13049 ng•hr/ml,13049,25.1 L/h,-,97%,0.000543708,1998,"Neuro Oncol 2008, 10(2): 190",http://www.ncbi.nlm.nih.gov/pubmed/18287342,http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2613821/,https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Celecoxib,not approved for cancer indications,"not approved for cancer indications. At recommended anti-inflammatory dose (200 mg PO), Cmax= 705 ng/ml, Tmax= 2.8 h, T1/2= 11.2 h, Vss/F=429 L, Cl/F= 27.7 L/h",,
32,Ceritinib,Zykadia,Kinase inhibitor (Tyrosine): ALK,558,750,mg,PO,-,qd,1.21,1.21E-06,0.000674,674,0.67,674 ng/ml,5,41,"14,000 ng•hr/ml","14,000",53.9 L/h,4230 L,97%,,2014,FDA NDA 205755: Clinical Pharmacology and Biopharmaceutics Review,n/a,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/205755Orig1s000ClinPharmR.pdf,https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Ceritinib,"Lung (NSCLC): non-small cell lung cancer, ALK-positive metastatic NSCLC who have progressed on or are intolerant to crizotinib",PK results from multiple dose study.,,
33,Chlorambucil  ,Leukeran,Alkylating/DNA damage,304,0.2,mg/kg,PO,-,qd,1.62,1.62E-06,0.000492,492,0.49,492 ng/ml,0.83,1.3,883 ng•hr/mL,883,-,-,99%,3.68E-05,1957,Drug Product Label,n/a,http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/010669s032lbl.pdf,https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Chlorambucil,"Leukemia: chronic lymphatic (lymphocytic) leukemia, malignant lymphomas including lymphosarcoma, giant follicular lymphoma, and Hodgkin’s disease",,,
34,Chloroquine,Aralen,not defined; lysosomotropic agent,320,750,mg,PO,-,-,0.725,7.25E-07,0.000232,232,0.23,232 ng/ml,3.7,-,8385 ng•hr/ml,8385,-,-,55%,,1949,Eur J Clin Pharmacol (2009) 65:179–189,http://www.ncbi.nlm.nih.gov/pubmed/18810398,http://link.springer.com/article/10.1007%2Fs00228-008-0563-x,https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Chloroquine,not approved for cancer indications,not approved for cancer indications; tissues accumulate 200-700 times the plasma level according to Drug Product Label.,,
35,Cisplatin,Platinol,Alkylating/DNA damage,300,80,mg/m2,IV, 1 h,-,14.4,1.44E-05,0.004321,4321,4.3,14.4 umol/L,-,0.44,16.4 umol•h/L,42921,-,11-12 L/m2,n/a *,,1978,"J Clin Oncol 2002, 20(6): 1657",http://www.ncbi.nlm.nih.gov/pubmed/11896117,http://jco.ascopubs.org/content/20/6/1657.long,https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Cisplatin,"Testicular, Metastatic;  Metastatic Ovarian Tumors;  Advanced Bladder Cancer","Data are for intact cisplatin. * Cisplatin does not undergo instantaneous and reversible binding to plasma proteins. However, the platinum from cisplatin, but not cisplatin itself, becomes bound to several plasma proteins, including albumin, transferrin, and gamma globulin. Three hours after a bolus injection and two hours after the end of a three-hour infusion, 90% of the plasma platinum is protein bound.",,
36,Cladribine,Leustatin,Nucleoside/Antimetab: Adenosine deaminase inhibitor,286,0.09,mg/kg/day,IV,24 h,continuous for 7 d,0.02,2.00E-08,0.0000057,5.7,0.0057,5.7 ng/ml,-,-,-,-,663.5 ml/h/kg,-,20%,5.7 ng/ml,1993,Drug Product Label,n/a,http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020229s034lbl.pdf,https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Cladribine,Leukemia: Hairy Cell Leukemia,"continuous infusion, as recommended in label.  Reference for protein binding: Eur J Clin Pharmacol (1994) 46:563-564",,
37,Cladribine,Leustatin,Nucleoside/Antimetab: Adenosine deaminase inhibitor,286,0.12,mg/kg,IV,2 h,-,0.168,1.68E-07,0.000048,48,0.048,48 ng/ml,-,5.4,-,-,978 mL/h/kg,4.5 L/kg,20%,,1993,Drug Product Label,n/a,http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020229s034lbl.pdf,https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Cladribine,Leukemia: Hairy Cell Leukemia,single dose (2 h infusion): Cmax at end of infusion,,
38,Clofarabine  ,Clolar,Nucleoside/Antimetab: Ribonucleoside-Diphosphate Reductase Inhibitor;  DNA Polymerase Inhibitor ,304,40,mg/m2,IV,2 h, X 5 d,0.744,7.44E-07,0.000226,226,0.23,226 ng/ml,-,4.9,931 ng•hr/ml,931,1.6 L/h/kg,8.8 L/kg,47%,,2004,"J Clin Pharmacol 2011, 51(5): 679",http://www.ncbi.nlm.nih.gov/pubmed/20525919,http://onlinelibrary.wiley.com/doi/10.1177/0091270010372519/abstract,https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Clofarabine,Leukemia: Acute Lymphoblastic Leukemia:  pediatric patients 1 to 21 years old with relapsed or refractory ALL after at least two prior regimens,recommended pediatric dose is 52 mg/m2 IV 2 hr infusion.,,
39,Cobimetinib,Cotellic,Kinase inhibitor (Ser/Thr): MEK1/MEK2,531,60,mg,PO,-,qd,0.514,5.14E-07,0.000273,273,0.27,273 ng/ml,2.4,44,4340 ng•hr/ml,4340,13.8 L/h,806 L,95%,,2015,Drug Product Label,n/a,http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020229s034lbl.pdf,https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Cobimetinib,"Melanoma:  metastatic melanoma with a BRAF V600E or V600K mutation, Unresectable or Metastatic",,,
40,Crizotinib  ,Xalkori ,"Kinase inhibitor (Tyrosine): c-Met,  ALK, RON",450,250,mg,PO,-,BID,0.913,9.13E-07,0.000411,411,0.41,411 ng/ml,4,34.9,3880 ng•hr/ml,3880,64.5 L/h,4313 L,91%,,2011,FDA NDA 202570:  Clinical Pharmacology and Biopharmaceutic Review,n/a,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/202570Orig1s000ClinPharmR.pdf,https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Crizotinib,Lung (NSCLC): non-small cell lung cancer (metastatic) whose tumors are ALK-positive or ROS-1 positive,data from multiple dose day 15,,
41,Cyclophosphamide  ,Cytoxan,Alkylating/DNA damage,261,600,mg/m2,IV,bolus,-,128,1.28E-04,0.033408,33408,33,128 uM,-,12-Mar,51955 umol•min/L,226082,78 ml/min,-,20%,,1959,"Cancer Chemother Pharmacol 1994, 33(6): 472",http://www.ncbi.nlm.nih.gov/pubmed/8137456,http://link.springer.com/article/10.1007/BF00686503,https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Cyclophosphamide,"Lymphoma: Malignant lymphomas (Hodgkin’s disease, lymphocytic lymphoma (nodular or diffuse), mixed-cell type lymphoma, histiocytic lymphoma, Burkitt’s lymphoma);  Multiple myeloma;  Leukemias: Chronic lymphocytic leukemia, chronic granulocytic leukemia, acute myelogenous and monocytic leukemia, acute lymphoblastic (stem-cell) leukemia in children;  Mycosis fungoides (advanced disease);  Neuroblastoma (disseminated disease);  Adenocarcinoma of the ovary;  Retinoblastoma;  Carcinoma of the breast.",,,
42,Cytarabine,Cytosar-U,Nucleoside/Antimetab: DNA Polymerase inhibitor,243,3000,mg/m2,IV,3 h,-,54.4,5.44E-05,0.01329,13219,13.2,54.4 uM,-,3.82,160.2 umol•h/L,38928,1258 ml/min/m2,0.702 L/kg,13%,,1969,"Leukemia & Lymphoma (1997), 27: 321-327",https://www.ncbi.nlm.nih.gov/pubmed/9402329,http://dx.doi.org/10.3109/10428199709059686,https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Cytarabine,Leukemia: acute non-lymphocytic leukemia;  acute lymphocytic leukemia and the blast phase of chronic myelocytic leukemia;  meningeal leukemia," Multiple doses and infusion times are used; Single high dose shown here.  Label suggests 100-200 mg/m2/day by constant infusion, targeted Css with constant infusion is 20-35 uM",,
43,Dabrafenib,Tafinlar,"Kinase inhibitor (Ser/Thr): BRAF V600E,K,D mutants",520,150,mg,PO,-,BID,4.86,4.86E-06,0.002527,2527,2.5,2527 ng/ml,2,4.8,10751 ng•hr/ml,10751,14.0 L/hr,45.5 L,99.70%,,2013,Journal of Clinical Pharmacology 53(9) 955–961 (2013),http://www.ncbi.nlm.nih.gov/pubmed/23846776,http://onlinelibrary.wiley.com/doi/10.1002/jcph.127/abstract,https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Dabrafenib,"Melanoma:  BRAF V600E or V600K Mutation-Positive, Unresectable or Metastatic",approved for BRAF V600E mutant melanoma,,
44,Dacarbazine  ,DTIC-Dome ,Alkylating/DNA damage,182,200,mg/m2,IV,30 min,-,34.4,3.44E-05,0.00627,6270,6.3,6.27 ug/ml,-,5,4.86 mg•hr/L,4860,91.4 L/h,-,<5%,0.000202292,1975,"Anti-Cancer Drugs 2004, 15(5): 495 and Drug Product Label",http://www.ncbi.nlm.nih.gov/pubmed/15166624,http://ovidsp.tx.ovid.com/sp-3.18.0b/ovidweb.cgi?&S=GJMAFPAIFADDDDIJNCJKKHMCHHJIAA00&Link+Set=S.sh.22.23.27.31%7c11%7csl_10,https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Dacarbazine,Melanoma: malignant (metastatic); Hodgkin's disease,"enzymatically converted to MTIC via Cyp1A2, 2E1, 1A1",,
45,Dactinomycin,Cosmegen,DNA binding/RNA polymerase inhibitor,1255,0.70- 1.50,mg/m2,IV,bolus,-,0.02,2.00E-08,0.0000251,25,0.025,25.1 ng/ml,0.25,14-43,2.67 mg•min/L,44.5,68-203 ml/min/m2,-,5%,7.42E-06,1964,Clin Cancer Res. 2005 Aug 15;11(16):5893-9.,http://www.ncbi.nlm.nih.gov/pubmed/16115931,http://clincancerres.aacrjournals.org/content/11/16/5893.long,https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Dactinomycin,"Wilms’ tumor, childhood rhabdomyosarcoma, Ewing’s sarcoma and metastatic, nonseminomatous testicular cancer,  gestational trophoblastic neoplasia;   locally recurrent or locoregional solid malignancies.",,,
46,Dasatinib  ,Sprycel ,Kinase inhibitor (Tyrosine):  Multi-Kinases Including Bcr-Abl & Src,488,100,mg,PO,-,qd,0.264,2.64E-07,0.000129,129,0.13,129 ng/ml,2,6.2,478 ng•hr/ml,478,-,2505 L,96%,,2006,Clin Cancer Res. 2012;18:5489-98,http://www.ncbi.nlm.nih.gov/pubmed/22837181,http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3463759/,https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Dasatinib,"Leukemia: Chronic Myeloid Leukemia:  newly diagnosed Philadelphia chromosome-positive (Ph+) CML in chronic phase;  chronic, accelerated, or myeloid or lymphoid blast phase Ph+ CML with resistance or intolerance to prior therapy including imatinib;  Acute Lymphoblastic Leukemia (Ph+ ALL) with resistance or intolerance to prior therapy",,,
47,Daunorubicin,Daunoxome ,Topo II /DNA intercalating,564,50,mg/m2,IV,1 h,-,0.31,3.10E-07,0.00017,175,0.17,0.31 umol/L,-,11,1.02 umol•hr/L,575,0.21 umol/h,-,97%,,1987,Ther Drug Monit 2007;29:626–631,http://www.ncbi.nlm.nih.gov/pubmed/17898654,http://journals.lww.com/drug-monitoring/pages/articleviewer.aspx?year=2007&issue=10000&article=00012&type=abstract,https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Daunorubicin,"Leukemia: Acute Nonlymphocytic Leukemia (myelogenous, monocytic, erythroid) of adults ;  Acute Lymphocytic Leukemia of children and adults",data are for standard formulation; liposomal formulation yields 100X higher exposure,,
48,Decitabine  ,Dacogen ,Nucleoside/Antimetab: DNA Methyltransferase (DNMT) Inhibitor;  demethylating agent,228,15,mg/m2,IV, 3 h,TID X3d,0.323,3.23E-07,0.0000738,74,0.074,73.8 ng/ml,2.5,0.62,163 ng•hr/ml,163,125 L/h.m2,71.8 L/m2,<1%,,2006,"Drug Product Label and Cancer Chemother Pharmacol 2008, 61(5): 759-766",http://www.ncbi.nlm.nih.gov/pubmed/17564707,http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021790s018lbl.pdf,https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Decitabine,"Myelodysplastic Syndromes (MDS):  all French-American-British subtypes (refractory anemia, refractory anemia with ringed sideroblasts, refractory anemia with excess blasts, refractory anemia with excess blasts in transformation, and chronic myelomonocytic leukemia).",,,
49,Degarelix,Firmagon,GnRH antagonist,1632,240,mg,SC,-,-,0.016,1.61E-08,0.0000262,26,0.026,26.2 ng/mL,48,-,1054 ng•day/ml,25296,-,-,90%,,2008,Drug Product Label,n/a,http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/022201s009lbl.pdf,https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Degarelix,Prostate ,"Forms a depot upon subcutaneous administration, from which degarelix is released to the circulation.",,
50,Dexrazoxane   ,Zinecard  ,Chemoprotective: chelator,268,500,mg/m2,IV,15 min,-,136,1.36E-04,0.0365,36500,37,36.5 ug/ml,-,2.5,-,-,7.88 L/h/m2,22.4 L/m2,<2%,,1995,Drug Product Label; see also:  J Clin Pharmacol. 2011 May;51(5):731-8.  ,http://www.ncbi.nlm.nih.gov/pubmed/20484616,http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/020212s017lbl.pdf,https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Dexrazoxane,Breast:  reducing the incidence and severity of cardiomyopathy associated with doxorubicin administration in women with metastatic breast cancer who have received a cumulative doxorubicin dose of 300 mg/m2,Used as cardioprotectant in combination with doxorubicin,,
51,Docetaxel  ,Taxotere ,Tubulin: microtubule stabilizing,808,100,mg/m2,IV,1 h,-,5.47,5.47E-06,0.00442,4420,4.4,4.42 ug/ml,-,41,5.9 ug•hr/ml,5900,35 L/h,477 L,97%,,1996,"Clin Pharmacol Ther 2004, 75(5): 448",http://www.ncbi.nlm.nih.gov/pubmed/15116057,http://onlinelibrary.wiley.com/doi/10.1016/j.clpt.2004.01.001/abstract,https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Docetaxel,Breast:  Non-Small Cell Lung Cancer;  Prostate Cancer;  Gastric Adenocarcinoma;  Head and Neck Cancer,,,
52,Doxorubicin   ,Adriamycin ,Topo II /DNA intercalating,544,60,mg/m2,IV,5 min,-,6.73,6.73E-06,0.00366,3660,3.7,3.66 ug/ml,-,14.2,1.85 ug•hr/ml,1850,-,762 L/m2,75%,,1974,"Anti-Cancer Drugs 1999, 10(8): 719",http://www.ncbi.nlm.nih.gov/pubmed/10573204,http://ovidsp.tx.ovid.com/sp-3.18.0b/ovidweb.cgi?WebLinkFrameset=1&S=FOANFPMHDKDDDDDMNCJKAFOBHBBIAA00&returnUrl=ovidweb.cgi%3fMain%2bSearch%2bPage%3d1%26S%3dFOANFPMHDKDDDDDMNCJKAFOBHBBIAA00&directlink=http%3a%2f%2fgraphics.tx.ovid.com%2fovftpdfs%2fFPDDNCO,https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Doxorubicin,"Breast: adjuvant of multi-agent chemotherapy;  Acute Lymphoblastic Leukemia;  Acute Myeloblastic Leukemia;  Hodgkin lymphoma;  non-Hodgkin lymphoma (NHL);  Metastatic: breast cancer, Wilms' tumor, neuroblastoma, soft tissue sarcoma, bone sarcoma,  ovarian carcinoma, transitional cell bladder carcinoma, thyroid carcinoma,  gastric carcinoma, bronchogenic carcinoma",,,
53,Doxorubicin  (liposomal),Doxil,Topo II /DNA intercalating,544,20,mg/m2,IV,30 min,q 3 wk,15.34,1.53E-05,0.00834,8340,8.3,8.34 ug/ml,-,55,590 ug•hr/ml,590000,0.041 L/h/m2,2.72 L/m2,70%,,1995,Drug Product Label,,http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/050718s048lbl.pdf,https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Doxil,Ovarian; Multiple Myeloma; AIDS-related Kaposi's Sarcoma,recommended dose for ovarian cancer is 50 mg/m2 IV q 4 wk,,
54,Dutasteride,Avodart,Steroid metabolism: 5-Alpha Reductase Inhibitor,529,0.5,mg,PO,-,qd,0.076,7.57E-08,0.00004,40,0.04,40 ng/ml,3-Feb,840,-,-,-,300-500 L,99%,,2001,Drug Product Label,n/a,http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/021319s028s029lbl.pdf,https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Avodart,not approved for cancer indications.  Prostate: benign prostatic hyperplasia ,not approved for cancer indications: Approved for BPH. Cmax is given as steady state concentration.  Dutasteride is highly bound to plasma albumin (99.0%) and alpha-1 acid glycoprotein (96.6%).,,
55,Enzalutamide,Xtandi,Androgen Receptor Antagonist,464,160,mg,PO,-,qd,35.7,3.57E-05,0.0166,16600,17,16.6 ug/ml,1,5.8,-,-,0.56 L/h,110 L,98%,,2012,Drug Product Label,n/a,http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/203415s007lbl.pdf,https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Enzalutamide,Prostate:  metastatic castration-resistant prostate cancer who have previously received docetaxel,"Active metabolite (CYP2C8, 3A4) is N-desmethyl enzalutamide, Cmax is 12.7 ug/ml.  previously named MDV 3100",,
56,Epirubicin   ,Ellence ,Topo II,544,120,mg/m2,IV,10 min,-,16.6,1.66E-05,0.009,9000,9,9.0 ug/ml,-,33.7,3.4 ug•hr/ml,3400,65 L/h,23 L/kg,77%,,1999,Drug Product Label,n/a,http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/050778s021lbl.pdf,https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Epirubicin,Breast: as a component of adjuvant therapy in patients with evidence of axillary node tumor involvement following resection of primary breast cancer,,,
57,Eribulin Mesylate  ,Halaven ,Tubulin: inhibition,730,1.4,mg/m2,IV,2-5 min,-,0.508,5.08E-07,0.000371,371,0.37,371 ng/ml,0.17,40.4,757 ng•hr/ml,757,3.41 L/h,134 L,49-65%,,2010,"Br J Clin Pharmacol 2013, 75:507-515",http://www.ncbi.nlm.nih.gov/pubmed/22803519,http://onlinelibrary.wiley.com/doi/10.1111/j.1365-2125.2012.04381.x/abstract,https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Eribulin,Breast: metastatic breast cancer who have previously received at least two chemotherapeutic regimens for the treatment of metastatic disease,,,
58,Erlotinib   ,Tarceva ,Kinase inhibitor (Tyrosine): EGFR,393,150,mg,PO,-,qd,3.15,3.15E-06,0.001238,1238,1.2,1.238 ug/ml,5.5,24.4,18.6 ug•hr/L,18.6,6.33 L/h,136 L,93%,,2004,"J Clin Oncol 2001, 19(13): 3267-3279; and  Drug Product Label ",http://www.ncbi.nlm.nih.gov/pubmed/11432895,http://jco.ascopubs.org/content/19/13/3267.long,https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Erlotinib,Lung (NSCLC): Non-Small Cell Lung Cancer;  Pancreatic Cancer,,,
59,Estramustine phosphate,Emcyt,Alkylating/DNA damage; Tubulin  inhibitor ,520,2000,mg/m2,IV,60 min,qw,797,7.97E-04,0.41,414700,415,797 umol/L,-,2.5,1710 umol•hr/L,889884,4.6 L/h,10.3 L,-,,1980,"J Clin Oncol 2002, 20(4): 1115",http://www.ncbi.nlm.nih.gov/pubmed/11844837,http://jco.ascopubs.org/content/20/4/1115.long,https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Estramustine,Prostate:  metastatic and/or progressive carcinoma of the prostate,prodrug for estramustine;  Data are for recommended Phase II dose.  Label recommends 14 mg/kg PO.,,
62,Etoposide  ,VePesid ,Topo II /DNA binding,589,100,mg/m2,IV,60 min,-,33.4,3.34E-05,0.01966,19660,20,19.7 mg/L,-,3.62,29.8 ug•hr/ml,29800,5.37 L/h,29.8 L,97%,,1983,"Anti-Cancer Drugs 1999, 10(4): 361",http://www.ncbi.nlm.nih.gov/pubmed/10378670,http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=linkout&SEARCH=10378670.ui,https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Etoposide,Lung: Small Cell Lung Cancer;  Refractory Testicular Tumors,Patients received etoposide in combination with cisplatin and Ro 40-8757,,
63,Everolimus  ,Afinitor ,"Immunomodulator: FKBP-12 binding, mTOR inhibitor",958,10,mg,PO,-,qd,0.064,6.37E-08,0.000061,61,0.061,61 ng/ml,1,-,514 ng•hr/ml,514,-,-,74%,,2009,"Eur J Cancer 2008, 44(1): 84",http://www.ncbi.nlm.nih.gov/pubmed/18039566,http://www.sciencedirect.com/science/article/pii/S0959804907007939,https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Everolimus,"Breast:  Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer;  Advanced Neuroendocrine Tumors of Pancreatic Origin (PNET);  Advanced Renal Cell Carcinoma (RCC);  Renal Angiomyolipoma with Tuberous Sclerosis Complex (TSC);  Subependymal Giant Cell Astrocytoma (SEGA) with Tuberous Sclerosis Complex (TSC);   Neuroendocrine Tumors of Lung Origin",,,
64,Exemestane  ,Aromasin ,Steroid metabolism: Aromatase Inhibitor,296,25,mg,PO,-, q.d.,0.027,2.67E-08,0.0000079,7.9,0.0079,7.9 ng/ml,1.2-2.9,24,52 ng•hr/ml,52,-,-,90%,,1999,"Breast Cancer Res Treat 2008, 111(2): 377-388 and Drug Product Label",http://www.ncbi.nlm.nih.gov/pubmed/17952589,http://link.springer.com/article/10.1007%2Fs10549-007-9787-1,https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Exemestane,Breast:  adjuvant treatment of postmenopausal women with estrogen-receptor positive early breast cancer who have received two to three years of tamoxifen;   Advanced Breast Cancer,Data are following 2 weeks of repeated daily dosing,,
65,Finasteride,Proscar,Steroid metabolism: 5-Alpha Reductase Inhibitor,373,5,mg,PO,-,qd,0.124,1.24E-07,0.0000462,46,0.046,46.2 ng/ml,1.8,6,389 ng•hr/ml,389,165 mL/min,76 L,90%,,1992,Drug Product Label,n/a,http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/020180s044lbl.pdf,https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Finasteride,not approved for cancer indications;  Prostate: benign prostatic hyperplasia ,not approved for cancer indications: Approved for BPH,,
66,Floxuridine,FUDR,Nucleoside/Antimetab: Pyrimidine antagonist,246,30,mg/kg,IV,8 h,-,1.05,1.05E-06,0.000259,259,0.26,258.8 ug/L,-,0.22,81.9 mg•min/L,1365,22.4 L/min,-,-,,1970,"J Clin Pharmacol. 2004, 44(11):1260-72",http://www.ncbi.nlm.nih.gov/pubmed/15496644,http://onlinelibrary.wiley.com/doi/10.1177/0091270004268911/abstract,https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Floxuridine,"Gastrointestinal adenocarcinoma metastatic to the liver,",Discontinued.  5-FU prodrug.  Cmax varies widely based on dose and infusion rate.  AUC given as sum of Floxuridine (parent) and 5-FU,,
70,Fluorouracil  (5-FU),Adrucil,Nucleoside/Antimetab: Pyrimidine antagonist,130,400,mg/m2,IV,push,-,426,4.26E-04,0.0554,55400,55,55.4 ug/ml,-,-,11.59 ug•hr/ml,11590,30.64 L/h/m2,-,10%,,1962,"Pharmacol Res 2004, 50(2): 173",http://www.ncbi.nlm.nih.gov/pubmed/15177306,http://www.sciencedirect.com/science/article/pii/S1043661804000246,https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Fluorouracil,"Colon: carcinoma of the colon, rectum, breast, stomach and pancreas.",,,
71,Flutamide,Eulexin,Androgen Receptor Antagonist,276,250,mg,PO,-,-,0.409,4.09E-07,0.000113,113,0.11, 113 ng/ml,1.3,7.8,-,-,-,-,94-96%,,1989,Drug Product Label,n/a,http://www.accessdata.fda.gov/drugsatfda_docs/label/2001/18554s23lbl.pdf,https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Flutamide,"Prostate, metastatic carcinoma","PK parameters given are after steady state is reached.  Cmax after single dose is 25.2 ng/ml.  Flutamide is rapidly metabolized to the active metabolite, Hydroxyflutamide, which reaches Cmax of 1629 ng/ml at steady state.",,
72,Fulvestrant  ,Faslodex ,Estrogen Receptor Antagonist,607,500,mg,IM,-,-,0.041,4.14E-08,0.0000251,25,0.025,25.1 ng/ml,-,960,11400 ng•hr/ml,11400,690 ml/min,3-5 L/kg,99%,,2002,Drug Product Label; see also Br J Cancer. 1996 Jul;74(2):300-8.,http://www.ncbi.nlm.nih.gov/pubmed/8688341,http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2074590/,https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Fulvestrant,Breast:  hormone receptor positive metastatic breast cancer,,,
73,Gefitinib  ,Iressa ,Kinase inhibitor (Tyrosine): EGFR,447,250,mg,PO,-,qd,0.356,3.56E-07,0.000159,159,0.16,159 ng/ml,3,50.5,5115 ng•hr/ml,5115,514 ml/min,1400 L,90%,,2003,Clin Pharmacokinet 2005; 44 (11): 1165-1177,http://www.ncbi.nlm.nih.gov/pubmed/16231967,http://link.springer.com/article/10.2165%2F00003088-200544110-00004,https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Iressa,Lung (NSCLC): locally advanced or metastatic non-small cell lung cancer after failure of both platinum-based and docetaxel chemotherapies,June 2005: FDA withdrew approval for use in new patients due to lack of evidence that it extended life.,,
74,Gemcitabine   ,Gemzar ,Nucleoside/Antimetab: Pyrimidine antagonist;  DNA synthesis inhibitor,263,1250,mg/m2,IV, 30 min,-,89.3,8.93E-05,0.0235,23500,24,23.5 ug/ml,-,0.23,12.5 ug•hr/ml,12500,3530 ml/min,25.9 L,negligible,,1996,"Cancer Chemother Pharmacol 2005, 55(6): 522",http://www.ncbi.nlm.nih.gov/pubmed/15754203,http://link.springer.com/article/10.1007%2Fs00280-004-0950-7,https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Gemcitabine,Ovarian: Breast Cancer;  Non-Small Cell Lung Cancer; Pancreatic Cancer,,,
75,Goserelin acetate,Zoladex,GnRH agonist,1269,10.8,mg,SC,-,-,0.007,6.97E-09,0.00000885,8.9,0.0089,8.85 ng/ml,1.8,-,-,-,121 ml/min,44.1 L,27%,,1989,Drug Product Label,n/a,"http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/019726s059,020578s037lbl.pdf",https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Goserelin,Prostate,Approval in 1996 for 10.8 mg implant; initial approval in 1989 for 3.6 mg dose,,
76,Histrelin acetate,Supprelin,GnRH agonist,1324,0.0567,mg/day,SC,,continuous release over 12 months,0.00083,8.31E-10,0.0000011,1.1,0.0011,1.1 ng/ml,12,-,13.8 ng.wk/ml,2318,-,-,70%,0.265 ng/ml,1991,J Clin Pharmacol. 2005 Nov;45(11):1245-9.,http://www.ncbi.nlm.nih.gov/pubmed/16239357,http://onlinelibrary.wiley.com/doi/10.1177/0091270005281043/abstract,https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Histrelin,not approved for cancer indications;  Approved for the treatment of children with central precocious puberty,not approved for cancer indications;  initial approval in 1991 for the treatment of children with central precocious puberty ,,
77,Hydroxychloroquine,Plaquenil,not defined; lysosomotropic agent,336,200,mg,PO,-,-,0.35,3.50E-07,0.0001174,117.4,0.1174,117.4 ng/ml,3.8,564,12015 ng•hr/ml,12015,-,-,45%,,1955,FDA ANDA 40274  Bioequivalence Review,n/a,http://www.accessdata.fda.gov/drugsatfda_docs/anda/98/40-274_Hydroxychloroquine%20Sulfate_Bioeqr.pdf,https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Hydroxychloroquine,"not approved for cancer indications; indicated for malaria.  Also indicated for the treatment of discoid and systemic lupus erythematosus, and rheumatoid arthritis.",not approved for cancer indications.  Cmax and PK parameters given for whole blood,,
78,Hydroxyurea,Droxia,Nucleoside/Antimetab: Ribonucleoside-Diphosphate Reductase Inhibitor,76,2000,mg,PO,-,qd,795,7.94E-04,0.06,60441,60,794.75 umol/L,1.2,3.32,3934 umol•hr/L,299181,124.83 ml/min,19.65 L/m2,-,,1967,"Blood 1998, 91(5): 1533",http://www.ncbi.nlm.nih.gov/pubmed/9473217,http://www.bloodjournal.org/content/91/5/1533.long?sso-checked=true,https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Hydroxyurea,"Melanoma, resistant Chronic Myelocytic Leukemia, and recurrent, metastatic, or inoperable Carcinoma of the Ovary,  Head and Neck primary squamous cell (epidermoid) carcinomas","see also:  J Clin Oncol 2005, 23(36): 9359",,
79,Ibandronate,Boniva,Osteoclast inhibitor,319,6,mg,IV, 30 min,-,1.02,1.02E-06,0.000327,327,0.33,327 ng/ml,0.63,12,56.5 ug•min/ml,942,141 ml/min,> 90 L,86%,,2003,"J Clin Pharmacol 2007, 47(8): 942",http://www.ncbi.nlm.nih.gov/pubmed/17615253,http://onlinelibrary.wiley.com/doi/10.1177/0091270007301801/abstract,https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Ibandronate,not approved for cancer indications;  Postmenopausal Osteoporosis,not approved for cancer indications;  approved for the treatment of osteoporosis in postmenopausal women,,
80,Ibrutinib,Imbruvica,Kinase inhibitor (Tyrosine): Btk (irreversible),441,560,mg,PO,-,q.d.,0.277,2.77E-07,0.000122,122,0.12,122 ng/ml,2,9.2,1263 ng•hr/ml,1263,1000 L/h,10000 L,98%,,2013,FDA NDA 205552: Clinical Pharmacology and Biopharmaceutics Review,n/a,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/205552Orig1s000ClinPharmR.pdf,https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Ibrutinib,Lymphoma: Mantle Cell Lymphoma;  Chronic Lymphocytic Leukemia;  Chronic Lymphocytic Leukemia with 17p deletion; Waldenstrom’s macroglobulinemia (WM),PK data from multi-dose study #1104-CA,,
81,Idarubicin,Idamycin,Topo II /DNA binding,498,15,mg/m2,IV,5 min,-,0.123,1.23E-07,0.0000612,61,0.061,61.2 ng/ml,-,21.8,173 ng•hr/ml,173,,-,97%,,1990,Cancer Chemother Pharmacol. 2004 Jan;53(1):61-7,http://www.ncbi.nlm.nih.gov/pubmed/12955471,http://link.springer.com/article/10.1007%2Fs00280-003-0700-2,https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Idarubicin,Leukemia: acute myeloid leukemia (AML) in adults. This includes French-American-British (FAB) classifications M1 through M7,"Idarubicinol (active metabolite) Cmax= 10.4 ng/ml (20.8 nM), T1/2= 47 hr, AUC= 747 ng.hr/ml",,
82,Idelalisib ,Zydelig ,Kinase inhibitor: PI3K delta,415,150,mg,PO,-,BID,5.18,5.18E-06,0.002152,2152,2.2,2152 ng/ml,1.8,5.75,9599 ng•hr/ml,9599,14.9 L/h,23 L,84%,,2014,FDA NDA 206545: Clinical Pharmacology and Biopharmaceutics Review,n/a,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/206545Orig1s000ClinPharmR.pdf,https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Idelalisib,Leukemia: Relapsed Chronic Lymphocytic Leukemia;   Relapsed Follicular B-cell non-Hodgkin Lymphoma;   Relapsed Small Lymphocytic Lymphoma,Values for Cl and Vd from Drug Product Label,,
83,Ifosfamide  ,Ifex ,Alkylating/DNA damage,261,3000,mg/m2,IV, 3 h,-,431,4.31E-04,0.11,112534,113,431 uM,-,4.1,9379 umol•h/L,2448857,,-,negligible,,1988,"Cancer Chemother Pharmacol 2007, 60(3): 375",http://www.ncbi.nlm.nih.gov/pubmed/17106751,http://link.springer.com/article/10.1007%2Fs00280-006-0373-8,https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Ifosfamide,Testicular  (germ cell),"with 24 h infusion, Cmax is 163 uM.",,
84,Imatinib,Gleevec,"Kinase inhibitor (Tyrosine): BCR-Abl, Kit, PDGFR",494,600,mg,PO,-,-,7.5,7.50E-06,0.0037,3700,3.7,3.7 ug/ml,-,17,48.8 ug•hr/ml,48800,8-14 L/hr,-,95%,,2001,"Clin Cancer Res 2003, 9(16): 5880",http://www.ncbi.nlm.nih.gov/pubmed/14676110,http://clincancerres.aacrjournals.org/content/9/16/5880.long,https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Imatinib,Leukemia: Chronic Myeloid Leukemia: Philadelphia Positive (Ph+ CML);  Acute Lymphoblastic Leukemia: Ph+ ALL;  Myelodysplastic/Myeloproliferative Diseases (MDS/MPD): associated with PDGFR gene re-arrangements;  Aggressive Systemic Mastocytosis (ASM);  Hypereosinophilic Syndrome (HES) and/or Chronic Eosinophilic Leukemia (CEL);   Dermatofibrosarcoma Protuberans (DFSP);   Kit+ Gastrointestinal Stromal Tumors (GIST);  Adjuvant Treatment of GIST,,,
85,Imiquimod  ,Aldara ,Immunomodulator: TLR7 Receptor Agonist,240,75,mg,topical,-,3X/wk for 16 wk,0.0056,5.62E-09,0.00000135,1.4,0.0014,1.35 ng/ml,-,-,29.1 ng•hr/L,0.0291,-,-,90-95%,,1997,"Arch Dermatol Res 2004, 296(1): 6",http://www.ncbi.nlm.nih.gov/pubmed/15083310,http://link.springer.com/article/10.1007%2Fs00403-004-0465-4,https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Imiquimod,Actinic Keratosis;   Superficial Basal Cell Carcinoma,"Cmax is mean at end of 16 week treatment. As topical agent, local tissue concentrations may be much greater than systemic exposure.",,
87,Irinotecan   ,Camptosar ,Topo I/DNA binding,587,340,mg/m2,IV,90 min,-,5.78,5.78E-06,0.003392,3392,3.4,3392 ng/ml,-,11.7,20604 ng•hr/ml,20604,13.9 L/hr/m2,234 L/m2,30-68%,,1996,Drug Product Label,n/a,http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/020571s048lbl.pdf,https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Irinotecan,Colon: metastatic carcinoma of the colon or rectum.,prodrug of SN-38,,
89,Irinotecan (liposomal),Onivyde ,Topo I/DNA binding,587,70,mg/m2,IV,90 min,-,63.4,6.34E-05,0.0372,37200,37,37.2 ug/ml,-,25.8,1364 ug•hr/ml,1364000,0.2 L/hr,4.1 L,<0.44%,,2015,Drug Product Label,n/a,http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/207793lbl.pdf,https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Onivyde,Pancreas:  metastatic adenocarcinoma of the pancreas after disease progression following gemcitabine-based therapy.,liposome formulation approved 10.22.15,,
91,Ixabepilone  ,Ixempra ,Tubulin: inhibition,507,40,mg/m2,IV,3 h,-,0.497,4.97E-07,0.000252,252,0.25,252 ng/ml,-,35,2143 ng•hr/ml,2143,352 ml/min/m2,1213 L/m2,67-77%,,2007,"Drug Product Label; see also Clin Cancer Res 2004, 10(4): 1289",http://www.ncbi.nlm.nih.gov/pubmed/14977827,http://clincancerres.aacrjournals.org/content/10/4/1289.long,https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Ixabepilone,"Breast: metastatic or locally advanced breast cancer in patients whose tumors are resistant or refractory to anthracyclines, taxanes, and capecitabine","data are for day 1, cycle 1; from label, 3 hr infusion yielded Cmax= 252 ng/ml",,
92,Ixazomib,Ninlaro,Proteosome inhibitor,517,4,mg,PO,-,-,0.118,1.18E-07,0.000061,61,0.061,61 ng/ml,1,228,1160  ng•hr/ml,1160,1.9 L/h,543 L,99%,,2015,FDA NDA 208462 Clinical Pharmacology and Biopharmaceutics Review,n/a,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/208462Orig1s000ClinPharmR.pdf,https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Ixazomib,Multiple Myeloma,,,
93,Lanreotide,Somatuline Depot,Somatostatin Agonist ,1096,120,mg,SC,-,q. 4 weeks,0.007,7.02E-09,0.0000077,7.7,0.0077,7.7 ng/ml,-,-,-,-,-,-,-,,2007,Drug Product Label,n/a,http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/022074s010lbl.pdf,https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Lanreotide,"Gastroenteropancreatic neuroendocrine tumors (GEP-NETs): unresectable, well or moderately differentiated, locally advanced or metastatic  ",oncology approval 12/16/2014.  Cmax at steady state.,,
94,Lapatinib,Tykerb ,"Kinase inhibitor (Tyrosine): ERBB2,  EGFR",581,1250,mg,PO,-,q.d. X 21 d,4.18,4.18E-06,0.00243,2430,2.4,2.43 ug/ml,4,14.2,36.2 ug•hr/ml,36200,-,-,>99%,,2007,"Drug Product Label; see also J Clin Oncol 2005, 23(23): 5305",http://www.ncbi.nlm.nih.gov/pubmed/15955900,http://jco.ascopubs.org/content/23/23/5305.long,https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Lapatinib,"Breast:  in combination with capecitabine for advanced or metastatic breast cancer whose tumors overexpress HER2 and who have received prior therapy including an anthracycline, a taxane, and trastuzumab",,,
95,Lenalidomide  ,Revlimid ,Immunomodulator: TNF-alpha Production Inhibitor,259,25,mg,PO,-,qd,1.74,1.74E-06,0.000451,451,0.45,451 ng/ml,1.5,5.3,3820 ng•hr/ml,3820,192 ml/min,57.9 L,30%,,2005,"J Clin Pharmacol 2009, 49(6): 650",http://www.ncbi.nlm.nih.gov/pubmed/19451403,http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2808857/,https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Lenalidomide,"Multiple Myeloma,  Myelodysplastic Syndromes,   Mantle Cell Lymphoma",,,
96,Lenvatinib ,Lenvima,"Kinase inhibitor (Tyrosine):  VEGFR1 (FLT1), VEGFR2 (KDR), and VEGFR3 (FLT4)",427,24,mg,PO,-,q.d.,0.761,7.61E-07,0.000325,325,0.33,325 ng/ml,2,28,3010 ng•hr/ml,3010,9.17 L/h,428 L,98-99%,,2015,Drug Product Label and FDA NDA 206947 Clinical Pharmacology and Biopharmaceutics Review,n/a,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/206947Orig1s000ClinPharmR.pdf,https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Lenvatinib,"Thyroid: locally recurrent or metastatic, progressive, radioactive iodine-refractory differentiated thyroid cancer (DTC).  In combination with everolimus, for the treatment of advanced renal cell carcinoma following one prior anti-angiogenic therapy.","PK data taken from Clinical Pharmacology and Biopharmaceutics Review of NDA 206947, Study E7080-A001-005",,
97,Letrozole  ,Femara ,Steroid metabolism: Aromatase Inhibitor,285,2.5,mg,PO,-,qd,0.406,4.06E-07,0.00012,116,0.12,406 nmol/L,1.5,-,7872 nmol•hr/L,2246,-,1.9 L/kg,60%,,1997,"Eur J Cancer 2008, 44(1): 84",http://www.ncbi.nlm.nih.gov/pubmed/18039566,http://www.sciencedirect.com/science/article/pii/S0959804907007939,https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Letrozole,Breast ,,,
98,Leuprolide Acetate,Eligard,GnRH agonist,1209,30,mg,SC,-,q. 4 months,0.124,1.24E-07,0.00015,150,0.15,150 ng/ml,3.3,-,-,-,8.34 L/h,27 L,43-49%,,2002,Drug Product Label; see also J Pharm Sci 1986; 75(2): 158–160,http://www.ncbi.nlm.nih.gov/pubmed/3083092,http://onlinelibrary.wiley.com/doi/10.1002/jps.2600750211/abstract,https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Leuprolide,Prostate ,Subcutaneous delivery provides sustained release.,,
102,Medroxyprogesterone acetate,Provera,Progesterone receptor agonist,387,20,mg,PO,-,-,0.0026,2.61E-09,0.00000101,1,0.001,1.01 ng/ml,2.7,12.1,6.95 ng•hr/ml,6.95,64110 ml/min,78024 L,90%,,1959,Drug Product Label,n/a,http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/011839s079s080lbl.pdf,https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Provera,not approved for cancer indications;  secondary amenorrhea and abnormal uterine bleeding;  endometrial hyperplasia,not approved for cancer indications,,
103,Megestrol acetate,Megace,Progesterone receptor agonist,385,800,mg,PO,suspension,q.d.,1.96,1.96E-06,0.000753,753,0.75,753 ng/ml,5,-,10476 ng•hr/ml,10476,-,-,-,,1971,"Drug Product Label; see also Cancer Chemother Pharmacol 1995, 36(4): 356",http://www.ncbi.nlm.nih.gov/pubmed/7628056,http://link.springer.com/article/10.1007/BF00689055,https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Megace,"Breast; Uterine Endometrial carcinoma,  Cachexia associated with AIDS",Given as a suspension. Data are following 21 day dosing at high dose,,
104,Melphalan,Alkeran,Alkylating/DNA damage,305,20,mg/m2,IV,15-20 min,-,9.17,9.17E-06,0.0028,2800,2.8,2.8 ug/mL,-,1.25,-,-,7-9 ml/min/kg,0.5 L/kg,60-90%,,1964,"Drug Product Label; for high dose see: Anticancer Res 1997, 17(1B): 605",http://www.ncbi.nlm.nih.gov/pubmed/9066587,http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/020207s016lbl.pdf,https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Melphalan,Multiple Myeloma; epithelial carcinoma of the ovary (oral tablet),IV Melphalan approved 1992,,
105,Mercaptopurine,Purinethol,Nucleoside/Antimetab: purine antagonist,152,75,mg/m2,PO,-,qd,0.59,5.90E-07,0.00008968,90,0.09,0.59 umol/L,-,1.3,1.8 umol•h/L,274,-,-,19%,,1953,"Blood 1998, 92(10): 3569",http://www.ncbi.nlm.nih.gov/pubmed/9808549,http://www.bloodjournal.org/content/92/10/3569.long?sso-checked=true,https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Mercaptopurine,"Leukemia: acute lymphatic leukemia (lymphocytic, lymphoblastic) ",high inter-patient variability,,
106,Mercaptopurine,Purixan,Nucleoside/Antimetab: purine antagonist,152,50,mg,PO,suspension,q.d.,0.625,6.25E-07,0.000095,95,0.095,95 ng/ml,-,2,136 ng•hr/ml,136,-,-,19%,,1953,Drug Product Label,n/a,http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/205919s000lbl.pdf,https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Purixan,Leukemia: acute lymphoblastic leukemia ,suspension formulation approved 04/28/2014 ,,
107,Metformin,Glucophage,not defined,129,1500,mg,PO,-,qd,24,2.40E-05,0.0031,3100,3.1,3.10 ug/ml,1.5,5.98,18.4 ug•hr/ml,18400,1552 ml/min,-,negligible,,1959,"Br J Clin Pharmac 1981, 12: 235-246",http://www.ncbi.nlm.nih.gov/pubmed/7306436,http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1401849/,https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Glucophage,not approved for cancer indications;  glycemic control in adults and children with type 2 diabetes mellitus,"not approved for cancer indications: Drug Product Label reports Cmax after 850 mg PO dose is 1.60 ug/ml in healthy adults, representing the average of means from five studies. ",,
108,Methotrexate  ,Abitrexate,Nucleoside/Antimetab: DHFR inhibitor,454,30,mg,PO,-,-,1.31,1.31E-06,0.000594,594,0.59,594 ug/L,1.2,2.9,2466 ug•hr/L,2466,8.4 L/h,-,50%,,1954,"J Rheumatol 2004, 31(4): 645",http://www.ncbi.nlm.nih.gov/pubmed/15088287,http://www.jrheum.org/content/31/4/645.long,https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Methotrexate,"Choriocarcinoma (gestational),  chorioadenoma destruens and hydatidiform mole;  acute lymphocytic leukemia, meningeal leukemia,  . breast cancer, epidermoid cancers of the head and neck, advanced mycosis fungoides (cutaneous T cell lymphoma), and lung cancer, particularly squamous cell and small cell types,  non-Hodgkin's lymphomas,  nonmetastatic osteosarcoma","PK is highly variable, esp. at high doses (>40 mg); Cmax as high as 1000 uM has been reported (Pediatr Pol. 1995 Nov;70(11):929-37)",,
109,Methoxsalen,Uvadex; 8-MOP,Alkylating/DNA damage,216,40,mg,PO,-,see notes,0.624,6.24E-07,0.000135,135,0.14,178 ng/ml,2,2,440 ng•hr/ml,440,-,-,90%,,1954,"J Clin Pharmacol 2006, 46(7): 768",http://www.ncbi.nlm.nih.gov/pubmed/16809802,http://onlinelibrary.wiley.com/doi/10.1177/0091270006288732/abstract,https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Methoxsalen,"Lymphoma: Cutaneous T-cell lymphoma, used in conjunction with extra-corporeal UV irradiation.","Approved 1999 for Cutaneous T-cell lymphoma.  Used in conjunction with extracorporeal UV irradiation with the UVAR instrument:  the white cell layer (buffy coat) is collected by centrifugation; red cells are returned to the patient and the UVADEX Sterile Solution is then injected into the instrument and mixed with the buffy coat. The instrument then irradiates this drug-cell mixture with ultraviolet light (UVA light, 320-400 nm) and returns the treated cells to the patient.",,
110,Mitomycin C,Mitozytrex,Alkylating/DNA damage,334,15,mg/m2,IV,30 min,-,2.18,2.18E-06,0.000729,729,0.73,729 ng/ml,-,0.81,691 ng•hr/ml,691,402 ml/min/m2,24.5 L/m2,24%,,1974,"Cancer 2001, 91(4): 815 ",http://www.ncbi.nlm.nih.gov/pubmed/11241251,http://onlinelibrary.wiley.com/doi/10.1002/1097-0142(20010215)91:4<815::AID-CNCR1069>3.0.CO;2-J/abstract,https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Mitomycin,Pancreatic: adenocarcinoma of the stomach or pancreas,"launched 1956;   protein binding found in: International Journal of Pharmacology, 2: 293-297 (2006)",,
111,Mitotane,Lysodren,Adrenal cytotoxic agent,320,6000,mg/day,PO,-,3-4 divided doses,50.9,5.09E-05,0.0163,16300,16,16.3 mg/L,-,432-3816,-,-,-,-,6%,,1970,"J Clin Endocrinol Metab 2011, 96:1844-1851 ",http://www.ncbi.nlm.nih.gov/pubmed/21470991,http://press.endocrine.org/doi/10.1210/jc.2010-2676?url_ver=Z39.88-2003&rfr_id=ori%3Arid%3Acrossref.org&rfr_dat=cr_pub=pubmed&,https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Mitotane,Adrenal cortical carcinoma,Median Cmax of responders is reported.  Plasma exposure above 14 mg/L correlates with clinical response.,,
112,Mitoxantrone ,Novantrone,Topo II /DNA binding,444,12,mg/m2,IV,30 min,-,0.715,7.15E-07,0.000318,318,0.32,318 ng/ml,-,17,298 ng•hr/ml,298,40.2 L/hr/m2,>1000 L/m2,78%,,1987,Cancer Chemother Pharmacol (2011) 67:431–438,http://www.ncbi.nlm.nih.gov/pubmed/20445979,http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3028086/,https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Mitoxantrone,"Prostate;   acute nonlymphocytic leukemia (ANLL) in adults,  including myelogenous, promyelocytic, monocytic, and erythroid acute leukemias.",alternate NSC# 301739,,
113,nab- Paclitaxel,Abraxane,Tubulin: microtubule stabilizing,854,260,mg/m2,IV,30 min,-,21.9,2.19E-05,0.01874,18740,19,18741 ng/ml,-,27,20324 ng•hr/ml,20324,15 L/hr/m2,632 L/m2,89-98%,,2005,"Drug Product Label; AUC from Clin Cancer Res 2008, 14(13): 4200",http://www.ncbi.nlm.nih.gov/pubmed/18594000,http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2661025/,https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Abraxane,"Breast: metastatic;  Non-Small Cell Lung Cancer,  Adenocarcinoma of the Pancreas",nanoparticle albumin-bound Paclitaxel.   09/09/2013:  Approved in combination with gemcitabine for the first-line treatment of patients with metastatic adenocarcinoma of the pancreas.,,
114,Nelarabine  ,Arranon ,Nucleoside/Antimetab: purine antagonist,297,1500,mg/m2,IV,2 h,-,16.8,1.68E-05,0.005,5000,5,5.0 ug/ml,-,0.3,4.4 ug•hr/ml,4400,197 L/h/m2,197 L/m2,<25%,,2005,"Drug Product Label; see also J Clin Oncol 1998, 16(11): 3607",http://www.ncbi.nlm.nih.gov/pubmed/9817282,http://jco.ascopubs.org/content/16/11/3607.long,https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Nelarabine,Leukemia: T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma,prodrug of ara-G,,
116,Nilotinib  ,Tasigna ,Kinase inhibitor (Tyrosine): BCR-Abl,530,400,mg,PO,-,BID,0.84,8.40E-07,0.000445,445,0.45,445 ng/ml,4,13,11.9 mg•hr/L,11900,50.5 L/h,-,98%,,2007,"J Clin Pharmacol 2010, 50(2): 188;  see also J Clin Pharmacol 2011, 51(1): 75",http://www.ncbi.nlm.nih.gov/pubmed/19948946,http://onlinelibrary.wiley.com/doi/10.1177/0091270009336137/abstract,https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Nilotinib,Leukemia: chronic myeloid leukemia (Ph+ CML) ( Philadelphia chromosome positive ),,,
117,Nilutamide,Nilandron,Androgen Receptor Antagonist,317,150,mg,PO,-,qd,2.84,2.84E-06,0.0009,900,0.9,0.9 ug/ml,2.8,56,39 ug•hr/ml,39000,-,-,80-84%,4.4 mg/L,1996,"Urology 1991, 37(2, Suppl.): 13",http://www.ncbi.nlm.nih.gov/pubmed/1992598,http://www.sciencedirect.com/science/article/pii/009042959180096P,https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Nilutamide,"Prostate, Metastatic",steady state concentration at 150 mg daily is approx 5X higher than single dose,,
118,Octreotide,Sandostatin,Somatostatin Agonist ,1033,0.1,mg,SC,-,-,0.0038,3.84E-09,0.00000397,4,0.004,3.97 ng/ml,0.64,2.25,12.4 ng•hr/ml,12.4,7-10 L/h,13.6 L,65%,,1988,"J Clin Endocrinol Metab, 2012, 97(7):2362–2369; and Drug Product Label",http://www.ncbi.nlm.nih.gov/pubmed/22539587,http://press.endocrine.org/doi/10.1210/jc.2012-1179?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub=pubmed,https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Octreotide,"Carcinoid Tumors,  Vasoactive Intestinal Peptide Tumors (VIPomas)",recommended dose is 50 ug SC twice or three times per day,,
119,Olaparib,Lynparza,PARP inhibitor,434,400,mg,PO,-,BID,13.1,1.31E-05,0.0057,5700,5.7,5.7 ug/ml,1.3,11.9,58 ug•hr/ml,58000,8.6 L/h,167 L,82%,,2014,Drug Product Label and NDA 206162 Clinical Pharmacology and Biopharmaceutics Review ,n/a,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/206162Orig1s000ClinPharmR.pdf,https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Olaparib,Ovarian:  germline BRCA mutated,Cmax aftermulti-dose  (Day 14) was 7.9 ug/ml. ,,
120,Omacetaxine,Synribo,Protein Translation Inhibitor: binds ribosomal A-site,546,1.25,mg/m2,SC,-,BID X 14 d,0.046,4.60E-08,0.0000251,25,0.025,25.1 ng/ml,0.55,7,136.2 ng•hr/ml,136,13.5 L/h/m2,127 L,50%,,2012,Cancer Chemother Pharmacol (2013) 71:35–41; and Drug Product Label,http://www.ncbi.nlm.nih.gov/pubmed/23053254,http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3535355/,https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Omacetaxine,Leukemia: chronic myeloid leukemia (CML),Cmax given for single dose; Cmax at steady state is 36.2 ng/ml. Mechanism:  protein translation inhibitor. It inhibits protein translation by preventing the initial elongation step of protein synthesis. It interacts with the ribosomal A-site and prevents the correct positioning of amino acid side chains of incoming aminoacyl-tRNAs. Omacetaxine acts only on the initial step of protein translation and does not inhibit protein synthesis from mRNAs that have already commenced translation.,,
121,Osimertinib,Tagrisso,"Kinase inhibitor (Tyrosine): EGFR, HER2,HER3, HER4, ACK1, BLK",500,80,mg,PO,-,qd,0.126,1.26E-07,0.000063,63,0.063,126.1 nM,6,64,6269 nmole•hr/L,3132,27.3 L/h,2495 L,99%,,2015,FDA NDA 208065:  Clinical Pharmacology and Biopharmaceutic Review,n/a,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/208065Orig1s000ClinPharmR.pdf,https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Osimertinib,Lung (NSCLC): metastatic epidermal growth factor receptor (EGFR) T790M mutation-positive non-small cell lung cancer,,,
122,Oxaliplatin  ,Eloxatin ,Alkylating/DNA damage,397,110,mg/m2,IV,2 h,-,4.96,4.96E-06,0.00197,1970,2,1.97 ug/ml,-,1.86,4.99 ug•hr/ml,4990,-,-,>90%,,2002,"Ann Oncol 2003, 14(12): 1776 ",http://www.ncbi.nlm.nih.gov/pubmed/14630684,https://annonc.oxfordjournals.org/content/14/12/1776.long,https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Oxaliplatin,Colon:  colorectal cancer,"Oxaliplatin shows irreversible plasma protein binding of  90%, so values are reported as ultrafilterable platinum.  Drug Product Label recommends dose of 85 mg/m2, reporting Cmax= 0.814 ug/ml.",,
123,Paclitaxel  ,Taxol,Tubulin: microtubule stabilizing,854,175,mg/m2,IV,3 h,-,4.27,4.27E-06,0.00365,3650,3.7,3650 ng/ml,-,20.2,15007 ng•hr/ml,15007,12.2 L/hr/m2,227-688 L/m2,89-98%,,1992,"Drug Product Label; for comparison with nab-Paclitaxel formulation, see Clin Cancer Res 2008, 14(13): 4200",http://www.ncbi.nlm.nih.gov/pubmed/18594000,http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2661025/,https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Paclitaxel,"Ovarian: breast cancer,  non-small cell lung cancer,  AIDS-related Kaposi’s sarcoma.",,,
124,Palbociclib,Ibrance,Kinase inhibitor (Ser/Thr): CDK4/6,448,125,mg,PO,-,q.d.,0.101,1.01E-07,0.00004524,45,0.045,45.24 ng/ml,6,22.2,1427 ng•hr/ml,1427,87.6 L/hr,2751 L,85%,,2015,"FDA NDA 207103 Clinical Pharmacology and Biopharmaceutics Review, Table 32",n/a,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/207103Orig1s000ClinPharmR.pdf,https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Palbociclib,"Breast: combination with letrozole in postmenopausal women with ER-positive, HER2-negative advanced breast cancer",,,
125,Pamidronate,Aredia,Osteoclast inhibitor,235,90,mg,IV,4 h,-,11.1,1.11E-05,0.00261,2610,2.6,2.61 ug/ml,4,-,17.12 ug•hr/ml,17120,103 ml/min,-,-,,1991,FDA NDA 20036 Pharm Tox review; data from Clinical Report 09 ,n/a,http://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/20-036_pharma_toxic_review.pdf,https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Pamidronate,"Hypercalcemia of malignancy; multiple myeloma;: treatment of moderate or severe hypercalcemia associated with malignancy, with or without bone metastases.",,,
126,Panobinostat,Farydak,HDAC inhibitor,349,20,mg,PO,-,TIW,0.082,8.24E-08,0.0000288,29,0.029,28.8 ng/ml,1,15.5,280 ng•hr/ml,280,86.4 L/h,1789 L,90%,,2015,"FDA NDA 205353 Clinical Pharmacology and Biopharmaceutics Review: Table 6, Study B2101: Day 15 (following dose 7) ",n/a,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/205353Orig1s000ClinPharmR.pdf,https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Panobinostat,Multiple Myeloma,"PK data from Day 15, following dose #7",,
127,Pazopanib   ,Votrient ,Kinase inhibitor (Tyrosine):  VEGF,438,800,mg,PO,-,-,133,1.33E-04,0.0581,58100,58,58.1 ug/ml,4-Feb,30.9,1037 ug•hr/ml,1037000,-,-,>99%,,2009,"Drug Product Label; see also Clin Pharmacol Ther. 2010, 88(6):818-23",http://www.ncbi.nlm.nih.gov/pubmed/20980999,http://onlinelibrary.wiley.com/doi/10.1038/clpt.2010.199/abstract,https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Pazopanib,"Kidney: renal cell carcinoma (RCC),  soft tissue sarcoma (STS)","significant food effects on bioavailability; food (high- or low-fat) increased Cmax, AUC and variability.",,
128,Pemetrexed,Alimta,Nucleoside/Antimetab: DHFR inhibitor,427,500,mg/m2,IV,10 min,-,306,3.06E-04,0.131,131000,131,131 ug/ml,-,4.4,188 ug•hr/ml,188000,93.2 ml/min,20.2 L,81%,,2004,"J Clin Oncol 2006, 24(4): 552",http://www.ncbi.nlm.nih.gov/pubmed/16391300,http://jco.ascopubs.org/content/24/4/552.long,https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Pemetrexed,"Lung (NSCLC): Nonsquamous Non-Small Cell Lung Cancer,  Mesothelioma",,,
129,Pentostatin,Nipent,Nucleoside/Antimetab: Adenosine deaminase inhibitor,268,4,mg/m2,IV,15 min,-,1.82,1.82E-06,0.000489,489,0.49,489 ng/ml,-,5.3,1232 ng•hr/ml,1232,114 ml/min,20 L/m2,4%,,1991,"Cancer Chemother Pharmacol 2002, 50(2): 121-126.  ",http://www.ncbi.nlm.nih.gov/pubmed/12172976,http://link.springer.com/article/10.1007%2Fs00280-002-0468-9,https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Pentostatin,Leukemia: Hairy Cell Leukemia,"Calculated mean Cmax from Table 3 (N=6, normal renal function);  measured by Enzyme assay; alternate LC/UV method (abstract) reports 60 uM with 4 mg/m2 (Proc Am Soc Clin Oncol (ASCO) 2002, 21(Part 2): Abst 479)",,
130,Plerixafor,Mozobil,Chemokine (CXCR4) antagonist,503,0.24,mg/kg,SC,-,-,1.84,1.84E-06,0.000926,926,0.93,926 ng/ml,0.5,5.1,4741 ng•hr/ml,4741,4767 ml/h,33.7 L,58%,,2008,"Biol Blood Marrow Transplant 2009, 15:39-46",http://www.ncbi.nlm.nih.gov/pubmed/19135941,http://www.sciencedirect.com/science/article/pii/S1083879108004527,https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Plerixafor,Lymphoma: non-Hodgkin’s lymphoma (NHL) and multiple myeloma (MM): to mobilize hematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation in patients ,,,
131,Pomalidomide ,Pomalyst,Immunomodulator: TNF-alpha Production Inhibitor,273,4,mg,PO,-,qd,0.274,2.74E-07,0.000075,75,0.075,75 ng/ml,3-Feb,9.5,400 ng•hr/ml,400,7-10 L/h,62-138 L,12-44%,,2013,Drug Product Label,n/a,http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/204026s005s006s008lbl.pdf,https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Pomalidomide,Multiple Myeloma,Black box warning for pregnancy.,,
132,Ponatinib,Iclusig,"Kinase inhibitor (Tyrosine): BCR-Abl; VEGFR, FGFR, Flt3, Tie2",533,45,mg,PO,-,qd,0.137,1.37E-07,0.000073,73,0.073,73 ng/ml,-,24,1253 ng•hr/ml,1253,-,1223 L,>99%,,2012,Drug Product Label,n/a,http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/203469s009lbl.pdf,https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Ponatinib,"Leukemia: chronic myeloid leukemia (CML),  acute lymphoblastic leukemia (Ph+ALL) T315I-positive Philadelphia chromosome positive",The Food and Drug Administration temporarily suspended sales of the drug in the U.S. on 31 October 2013 because of “the risk of life-threatening blood clots and severe narrowing of blood vessels”.,,
133,Porfimer,Photofrin,Photosensitizer,1179,2,mg/kg,IV,3-5 min,-,33.9,3.39E-05,0.04,40000,40,40 ug/ml,-,415,2400 ug•hr/ml,2400000,0.051 ml/min/kg,-,90%,,1995,Drug Product Label,n/a,http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/020451s023lbl.pdf,https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Porfimer,"Esophageal:  endobronchial non-small-cell lung cancer (NSCLC),  ablation of high-grade dysplasia in Barrett’s esophagus",Photodynamic therapy with PHOTOFRIN® is a two-stage process. The first stage is the intravenous injection of PHOTOFRIN®.  Illumination with 630 nm wavelength laser light constitutes the second stage of therapy. ,,
134,Pralatrexate  ,Folotyn ,Nucleoside/Antimetab: DHFR inhibitor,477,40,mg/m2,IV,5 min,-,10.3,1.03E-05,0.0049,4900,4.9,4.9 ug/ml,-,1.8,4.9 ug•hr/ml,4900,417 ml/min (S) and 191 ml/min ®,105(S) and 37(R)  L,67%,,2009,"Cancer Chemother Pharmacol 2006, 57(5): 671",http://www.ncbi.nlm.nih.gov/pubmed/16136310,http://link.springer.com/article/10.1007%2Fs00280-005-0080-x,https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Pralatrexate,Lymphoma: peripheral T-cell lymphoma (PTCL). ,given with probenecid 70 mg/m2 IV.  Recommended dose is 30 mg/m2.  Drug is mixture of R and S diastereomers,,
135,Prednisone,Deltasone,Immunomodulator: Glucocorticoid,358,50,mg,PO,-,-,0.145,1.45E-07,0.000052,52,0.052,52 ug/L,-,-,-,-,-,-,extensive,,1974,"J Pharmacokinet Biopharm 1981, 9(1): 1",http://www.ncbi.nlm.nih.gov/pubmed/7310640,http://link.springer.com/article/10.1007/BF01060885,https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Deltasone,"Leukemia and lymphoma in adults,  Acute leukemia of childhood",,,
136,Procarbazine   ,Matulane ,Alkylating/DNA damage,221,300,mg,PO,-,-,3.13,3.13E-06,0.000692,692,0.69,0.692 ug/ml,0.21,0.154,0.217 ug•hr/ml,217,35.8 L/min,435 L,-,,1969,"Anti-Cancer Drugs 2006, 17(1): 75;  see also Clin Cancer Res 2006, 12(17): 5174",http://www.ncbi.nlm.nih.gov/pubmed/16317293,http://journals.lww.com/anti-cancerdrugs/pages/articleviewer.aspx?year=2006&issue=01000&article=00010&type=abstract,https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Procarbazine,Lymphoma: Hodgkin's disease,,,
137,Quinacrine,Acrichine,NF-kappaB Activation Inhibitor; sPLA2 Inhibitor,400,100,mg,PO,-,TID,0.3,3.00E-07,0.00012,120,0.12,300-1000 nM,-,-,-,-,-,-,80-90%,,1932,Dement Geriatr Cogn Disord 2004;17:158–163,http://www.ncbi.nlm.nih.gov/pubmed/14739538,http://www.karger.com/Article/FullText/76350,unavailable,not approved for cancer indications,not approved for cancer indications; discontinued;   plasma levels of up to 2.5 micromolar were observed folloing 84 days of treatment at 300 mg/d;  long t1/2; pronounced tissue accumulation  ,,
138,Raloxifene   ,Evista,Estrogen Receptor agonist/antagonist; SERM,474,60,mg,PO,-,-,0.0011,1.06E-09,0.0000005,0.5,0.0005,0.5 (ng/ml)/(mg/kg),-,27.7,27.2 (ng•hr/ml)/(mg/kg),27.2 (ng•hr/ml)/(mg/kg),44.1 L/kg.hr,2348 L/kg,95%,,1997,"Drug Product Label; see also Breast Cancer Res Treat 2008, 111(2): 377",http://www.ncbi.nlm.nih.gov/pubmed/17952589,http://link.springer.com/article/10.1007%2Fs10549-007-9787-1,https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Evista,Breast:  Reduction in the Risk of Invasive Breast Cancer in Postmenopausal Women,"reported exposure normalized for dose (mg/kg), so exposure calculated for 60 kg patient (1 mg/kg); see also Breast Cancer Res Treat 2008, 111(2): 377, giving Cmax at 1.46 ng/ml",,
139,Regorafenib,Stivarga,"Kinase inhibitor (Tyrosine): RET/VEGFR/ RAF, others",483,160,mg,PO,-,qd,8.08,8.08E-06,0.0039,3900,3.9,3.9 ug/ml,4,28,58.3 ug•hr/ml,58300,-,-,99.50%,,2012,Drug Product Label,n/a,http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/203085s004lbl.pdf,https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Regorafenib,"Colon: colorectal Cancer,   Gastrointestinal Stromal Tumors","Cmax given for steady state; single dose Cmax is 2.5 ug/ml; AUC 70.4 ug.hr/ml.  Main circulating metabolites of regorafenib measured at steady-state in human plasma are M-2 (N-oxide) and M-5 (N-oxide and N-desmethyl), both of them having similar in vitro pharmacological activity and steady-state concentrations as regorafenib.",,
140,Romidepsin  ,Istodax ,HDAC inhibitor,541,14,mg/m2,IV,4 h,-,0.697,6.97E-07,0.000377,377,0.38,377 ng/ml,-,3,1549 ng•hr/ml,1549,11.6 L/h/m2,8.6 L/m2,92-94%,,2009,"Drug Product Label; see also Clin Cancer Res 2002, 8(3): 718",http://www.ncbi.nlm.nih.gov/pubmed/11895901,http://clincancerres.aacrjournals.org/content/8/3/718.long,https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Romidepsin,"Lymphoma: cutaneous T-cell lymphoma (CTCL),  peripheral T-cell lymphoma (PTCL)","Also known as depsipeptide, FK-228",,
141,Rucaparib,Rubraca,PARP inhibitor,323,600,mg,PO,,BID,6,6.00E-06,0.00194,1940,1.94,1940 ng/ml,1.9,17,16900 ng•hr/ml,16900,15.3 - 79.2 L/h,113-262 L,70%,,2016,Drug Product Label,n/a,http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/209115s000lbl.pdf,https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Rucaparib,Ovarian: patients with deleterious BRCA mutation (germline and/or somatic) associated advanced ovarian cancer who have been treated with two or more chemotherapies. Select patients for therapy based on an FDA-approved companion diagnostic for RUBRACA.,"In conjunction with the drug approval, FDA approved the FoundationFocus CDxBRCA test (Foundation Medicine Inc.), a next-generation sequencing (NGS)-based companion diagnostic to identify patients with advanced ovarian cancer eligible for treatment with rucaparib. The test detects alterations in BRCA1 and BRCA2 genes in the tumor tissue of ovarian cancer patients.",,
142,Ruxolitinib,Jakafi,"Kinase inhibitor (Tyrosine):  JAK1, JAK2",306,25,mg,PO,-,BID,1.09,1.09E-06,0.00033,335,0.33,1093 nM,0.63,2.3,3200 nmol•hr/L,979,-,-,97%,,2011,"Drug Metab Dispos 2010, 38(11): 2023",http://www.ncbi.nlm.nih.gov/pubmed/20699411,http://dmd.aspetjournals.org/content/38/11/2023.long,https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Ruxolitinib,Myelofibrosis; polycythemia vera,Dose (5-25 mg BID) is based on platelet count,,
143,Sildenafil,Viagra,PDE-5  cGMP-phosphodiesterase inhibitor,475,100,mg,PO,-,-,0.794,7.94E-07,0.000377,377,0.38,377 ng/ml,1,2.76,1295 ng•hr/ml,1295,-,105 L,96%,,1998,"Br J Clin Pharmacol 2010,  69 (1): 23–26; see also Br J Clin Pharmacol 2002,  53: 45S-52S; hi dose 200 mg yielded 2.18 uM Cmax.",http://www.ncbi.nlm.nih.gov/pubmed/20078609,http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2805874/,https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Sildenafil,not approved for cancer indications;  pulmonary arterial hypertension,"not approved for cancer indications:  active metabolite N-desmethyl (via cyp3A4) shows 50% potency, 40% exposure of parent",,
144,Sirolimus (Rapamycin),Rapamune,Immunomodulator: FKBP-12 binding,914,2,mg,PO,-,-,0.016,1.64E-08,0.000015,15,0.015,15.0 ng/ml,3.5,62,230 ng•hr/ml,230,139 ml/hr/kg,12 L/kg,92%,,1999,"Drug Product Label; see also Br J Cancer 2010, 103(11): 1637",http://www.ncbi.nlm.nih.gov/pubmed/21045832,http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2994217/,https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Sirolimus,not approved for cancer indications; Prophylaxis of Organ Rejection in Renal Transplantation,"not approved for cancer indications: 3A4 substrate; PK strongly influenced by concurrent 3A4 inhibitors, e.g., cyclosporine",,
145,Sonidegib,Odomzo,Smoothened receptor antagonist/ Hedge Hog inhibitor,485,200,mg,PO,-,q.d.,2.12,2.12E-06,0.00103,1030,1,1030 ng/ml,4-Feb,672,22 ug•hr/mL,22000,-,9166 L,>97%,,2015,Drug Product Label,n/a,http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/205266s000lbl.pdf,https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Sonidegib,Basal cell carcinoma,Cmax is estimated at steady state,,
146,Sorafenib ,Nexavar ,Kinase inhibitor (Tyrosine):  Multi-kinase,465,400,mg,PO,-,BID,20.1,2.01E-05,0.00935,9350,9.4,9.35 mg/L,2.5,23.8,107 mg•hr/L,107000,-,-,99.50%,,2005,"J Clin Oncol 2005, 23(5): 965",http://www.ncbi.nlm.nih.gov/pubmed/15613696,http://jco.ascopubs.org/content/23/5/965.long,https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Sorafenib,"Liver: Hepatocellular Carcinoma,  Renal Cell Carcinoma,  Differentiated Thyroid Carcinoma",Cmax  following multiple dosing,,
147,Streptozocin,Zanosar,Alkylating/DNA damage,265,1500,mg/m2,IV,push,-,1438,1.44E-03,0.38,381400,381,381.4 ug/ml,-,0.22,4329 ug•min/ml,72150,478 ug/min,-,-,,1982,J Clin Pharmacol. 1977 Jul;17(7):379-88,http://www.ncbi.nlm.nih.gov/pubmed/142097,http://onlinelibrary.wiley.com/doi/10.1002/j.1552-4604.1977.tb04620.x/abstract,https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Streptozocin,Pancreatic: metastatic islet cell carcinoma of the pancreas.,Maximum single dose is 1500 mg/m2,,
148,Sunitinib Malate  ,Sutent ,Kinase inhibitor (Tyrosine):  Multi-kinase,398,50,mg,PO,-,q.d. X 28 d,0.181,1.81E-07,0.0000722,72,0.072,72.2 ng/ml,8.5,41-86,1296 ng•hr/ml,1296,46.4 L/h,2230 L,95%,,2006,"J Clin Oncol 2006, 24(1):25-35",http://www.ncbi.nlm.nih.gov/pubmed/16314617,http://jco.ascopubs.org/content/24/1/25.long,https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Sunitinib,"Gastrointestinal Stromal Tumor (GIST),  Advanced Renal Cell Carcinoma (RCC),  Advanced Pancreatic Neuroendocrine Tumors (pNET)",Cmax following day 28 of daily administration; first dose Cmax= 27.7 ng/ml,,
149,Tacrolimus,Prograf,Immunomodulator: FKBP-12 binding,804,5,mg,PO,-,-,0.037,3.69E-08,0.0000297,30,0.03,29.7 ng/ml,1.6,34.8,243 ng•hr/ml,243,0.041 L/hr/kg,1.94 L/kg,99%,,1994,Drug Product Label,n/a,"http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/050708s045,050709s038lbl.pdf",https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Tacrolimus,"not approved for cancer indications;  Prophylaxis of Organ Rejection in Kidney,  Liver and Heart Transplant",not approved for cancer indications,,
150,Tamoxifen Citrate  ,Nolvadex ,Estrogen Receptor Antagonist,372,20,mg,PO,-,-,0.108,1.08E-07,0.00004,40,0.04,40 ng/ml,5,120-168,-,-,-,-,>99%,122 ng/ml,1977,Drug Product Label,n/a,http://www.accessdata.fda.gov/drugsatfda_docs/label/2006/017970s054lbl.pdf,https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Tamoxifen,Breast: metastatic;  Ductal Carcinoma in Situ (DCIS):,"see also: Clin Pharmacol Ther 1998, 64(6): 648 80 mg PO dose yields 145 ng/ml",,
151,Tegafur,Utefos,Nucleoside/Antimetab: Pyrimidine antagonist,200,50,mg/m2,PO,-,q.d.,19,1.90E-05,0.003803,3803,3.8,3083 ng/ml,1,7.88,26480 ng•hr/ml,26480,-,-,-,,1972,"Clinical Cancer Research 2002, 8, 2116–2122 ",http://www.ncbi.nlm.nih.gov/pubmed/12114411,http://clincancerres.aacrjournals.org/content/8/7/2116.long,unavailable,"Breast:  Carcinoma of bladder, Head and neck cancer, Liver carcinoma, Malignant tumor of digestive organ, Non-small cell lung cancer, Renal cell carcinoma
","5-FU prodrug; no current Drug Label available; has been used in Breast cancer, Carcinoma of bladder, Head and neck cancer, Liver carcinoma, Malignant tumor of digestive organ, Non-small cell lung cancer, Renal cell carcinoma",,
152,Temozolomide  ,Temodar ,Alkylating/DNA damage,194,150,mg/m2,IV,90 min,-,37.6,3.76E-05,0.0073,7300,7.3,7.3 ug/ml,1,1.8,24.6 ug•hr/mL,24600,5.5 L/h/m2,0.4 L/kg,15%,,1999,Drug Product Label; see also Clin Cancer Res. 2004 Mar 1;10(5):1645-56.,http://www.ncbi.nlm.nih.gov/pubmed/15014015,http://clincancerres.aacrjournals.org/content/10/5/1645.long,https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Temozolomide,"Brain: Glioblastoma Multiforme,  Refractory Anaplastic Astrocytoma",Active metabolite MTIC Cmax=276 ng/ml,,
154,Temsirolimus  ,Torisel ,"Immunomodulator: FKBP-12 binding, mTOR inhibitor",1030,25,mg,IV,30-60 min,-,0.568,5.68E-07,0.000585,585,0.59,585 ng/ml,-,17,1627 ng•h/mL,1627,-,-,87%,,2007,Drug Product Label,n/a,http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/022088s018lbl.pdf,https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Temsirolimus,Kidney: renal cell carcinoma,Sirolimus is an active metabolite,,
155,Teniposide,Vumon,Topo II ,657,300-750,mg/m2,IV,72 h,-,23.1,2.31E-05,0.0152,15200,15,15.2 mg/L **,-,-,-,-,-,-,>99%,15.2 mg/L,1992,"J Clin Oncol 5 (7), 1987: 1007-1014 ",http://www.ncbi.nlm.nih.gov/pubmed/3598607,http://jco.ascopubs.org/content/5/7/1007.long,https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Teniposide,Leukemia: childhood acute lymphoblastic leukemia.,** plasma steady state exposure in responders reported here;  high variability following brief injection; ,,
156,Testosterone enanthate,Delatestryl,Androgen Receptor Agonist,401,200,mg,IM,-,q. 2 wk,n.d.,n.d.,n.d.,n.d.,n.d.,n.d.,-,-,-,-,-,-,-,,1953,"J Clin Endocrinol Metab 1999, 84:3469-3478",http://www.ncbi.nlm.nih.gov/pubmed/10522982,http://press.endocrine.org/doi/10.1210/jcem.84.10.6078?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub=pubmed,https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=TESTOSTERONE+ENANTHATE,Breast: Metastatic mammary cancer ,exposure reported as testosterone,,
158,Thalidomide  ,Thalomid ,Immunomodulator: TNF-alpha Production Inhibitor,258,200,mg,PO,-,-,8.91,8.91E-06,0.0023,2300,2.3,2.30 ug/ml,5.8,4.12,23.3 ug•hr/ml,23300,9.09 L/h,53 L,55% (+)-(R);  66% (-)-(S),0.94 ug/ml,1998,Clin Pharmacol Ther. 1999 May;65(5):483-90.,http://www.ncbi.nlm.nih.gov/pubmed/10340913,http://onlinelibrary.wiley.com/doi/10.1016/S0009-9236(99)70067-6/abstract,https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Thalidomide,Multiple Myeloma,,,
159,Thioguanine,Tabloid,Nucleoside/Antimetab: purine antagonist,167,40,mg/m2,PO,-,q.d. x 4 wk,0.313,3.13E-07,0.00005233,52,0.052,313 pmol/ml,1.5,-,586 pmol•hr/L,0.0979,-,-,-,,1966,"Br J Clin Pharmacol 2001, 51(6): 531",http://www.ncbi.nlm.nih.gov/pubmed/11422012,http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2014483/,https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Thioguanine,Leukemia: Acute Nonlymphocytic Leukemias,"High variability; Rapidly converted to 6-thioguanylic acid (TGMP).There is technical difficulty in determining plasma concentrations of parent, which are seldom greater than 1 to 2 mcg/mL after a therapeutic oral dose. More significantly, thioguanine enters rapidly into the anabolic and catabolic pathways for purines, and the active intracellular metabolites have appreciably longer half-lives than the parent drug. ",,
160,Thiotepa,Thioplex,Alkylating/DNA damage,189,80,mg,IV,push,-,9.66,9.66E-06,0.001828,1828,1.8,1828 ng/ml,-,2.3,4127 ng•hr/ml,4127,419 ml/min,-,10%,,1959,Drug Product Label; protein binding found in: Cancer Chemother Pharmacol. 1987;20(4):319-23.,http://www.ncbi.nlm.nih.gov/pubmed/3121202,http://link.springer.com/article/10.1007/BF00262584,https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Thiotepa,"Breast:  Adenocarcinoma of the breast, ovary, papillary carcinoma of the urinary bladder.  For controlling intracavitary effusions secondary to diffuse or localized neoplastic diseases of various serosal cavities. ",Prodrug for TEPA,,
162,Topotecan   ,Hycamtin ,Topo I,421,2.3,mg/m2,PO,-,-,0.015,1.49E-08,0.0000063,6.3,0.0063,6.3 ng/ml,,3.49,22.7 ng•hr/ml,22.7,-,-,35%,,1996,"Br J Cancer 1999, 80(9): 1380",http://www.ncbi.nlm.nih.gov/pubmed/10424739,http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2363072/,https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Topotecan,"Lung: Small Cell Lung Cancer, relapsed",Data are for topotecan lactone; rapid interconversion between lactone and carboxylate;  Cmax for total (L + C) is 10.2 ng/ml.,,
163,Toremifene  ,Fareston ,Estrogen Receptor agonist/antagonist,406,120,mg,PO,-,-,4.56,4.56E-06,0.00185,1850,1.9,1.85 ug/ml,2.9,56.5,115.1 ug•hr/ml,115100,3.31 L/h,-,>99.5%,,1997,Breast Cancer (2009) 16:113–120,http://www.ncbi.nlm.nih.gov/pubmed/18936884,http://link.springer.com/article/10.1007%2Fs12282-008-0075-7,https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Toremifene,Breast:  metastatic,Dose recommended in label is 60 mg PO,,
164,Trabectedin ,Yondelis,Alkylating/DNA damage,762,1.5,mg/m2,IV,24 hr,q.3 weeks,0.0024,2.42E-09,0.00000184,1.8,0.0018,1.84 ng/ml,-,175,56.8 ng•hr/ml,56.8,57.7 L/h,7509 L,97%,,2015,FDA NDA 207953 Clinical Pharmacology and Biopharmaceutics Review,n/a,http://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/207953Orig1s000ClinPharmR.pdf,https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Trabectedin,Sarcoma: unresectable or metastatic liposarcoma or leiomyosarcoma,,,
165,Trametinib,Mekinist,"Kinase inhibitor (Tyrosine/Threonine): MEK1, 2 inhibitor",615,2,mg,PO,-,qd,0.021,2.11E-08,0.000013,13,0.013,13.0 ng/ml,2,3.9-4.8,69.7 ng•hr/ml,69.7,4.9 L/h,214 L,97%,,2013,"Eu J Cancer 2013, 49:2077-2085",http://www.ncbi.nlm.nih.gov/pubmed/23583440,http://www.sciencedirect.com/science/article/pii/S0959804913002232,https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Trametinib,Melanoma: unresectable or metastatic with BRAF V600E or V600K mutations,,,
166,Tretinoin,Vesanoid,RAR nuclear receptors,300,45,mg/m2,PO,-,,1.15,1.15E-06,0.000347,347,0.35,347 ng/ml,2.2,-,682 ng•hr/ml,682,-,-,>95%,,1995,"Cancer Res 1992, 52(8): 2138; and Drug Product Label",http://www.ncbi.nlm.nih.gov/pubmed/1559217,http://cancerres.aacrjournals.org/content/52/8/2138.long,https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Tretinoin,Leukemia: acute promyelocytic leukemia,rapid induction of metabolism reduces Cmax on repeated dosing,,
167,Triptorelin,Trelstar Depot,GnRH agonist,1311,22.5,mg,IM,-,q. 24 wk,0.034,3.36E-08,0.0000441,44,0.044,44.1 ng/ml,3-Jan,-,-,-,-,30-33 L,0%,,2000,Drug Product Label,n/a,"http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/020715s032,021288s028,022437s008lbl.pdf",https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Triptorelin,"Prostate, advanced",,,
168,Valrubicin,Valstar,Topo II,724,800,mg,Intra Cisternal,-,q. wk,0.011,1.11E-08,0.000008,8,0.008,plasma: 8 ng/ml  Bladder: 5-13 uM,6-Feb,-,78 nmol•hr/L,56.4,-,-,>99%,,1998,Drugs & Aging 1999 Jul; 15 (1): 69-75,http://www.ncbi.nlm.nih.gov/pubmed/10459733,http://link.springer.com/article/10.2165/00002512-199915010-00006,https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Valrubicin,Urinary bladder: intravesical therapy of BCG-refractory carcinoma in situ (CIS) of the urinary bladder ,note local delivery (intravesicular bladder); Bladder Cmax is 5-13 uM; systemic exposure is very low,,
169,Vandetanib,Caprelsa,"Kinase inhibitor (Tyrosine):  VEGFR, EGFR, RET",475,300,mg,PO,-,-,2.16,2.16E-06,0.001025,1025,1,1025 ng/ml,5,456,20460 ng•hr/ml,20460,13.2 L/h,7450 L,90%,,2011,"Ann Oncol 2009, 20(3): 486; and Drug Product Label",http://www.ncbi.nlm.nih.gov/pubmed/19088171,https://annonc.oxfordjournals.org/content/20/3/486.long,https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Vandetanib,Thyroid: medullary Thyroid Cancer,,,
170,Vemurafenib  ,Zelboraf ,Kinase inhibitor (Tyrosine):  B-Raf ,490,960,mg,PO,-,BID,127,1.27E-04,0.062,62000,62,62 ug/ml,3,57,601 ug•hr/ml,601000,31 L/d,106 L,>99%,,2011,Drug Product Label; see also N Engl J Med. 2010; 363:809-19.,http://www.ncbi.nlm.nih.gov/pubmed/20818844,http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3724529/,https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Vemurafenib,"Melanoma, metastatic with BRAF V600E mutation ",,,
171,Venetoclax,Venclexta,BCL-2 inhibitor,468,400,mg,PO,-,q.d.,4.48,4.48E-06,0.0021,21000,2.1,2.1 ug/ml,8-May,26,32.8  ug•hr/ml,32800,-,256-321 L,>99%,,2016,Drug Product Label,n/a,http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/208573s000lbl.pdf,https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Venetoclax,"Leukemia: chronic lymphocytic leukemia (CLL) with 17p deletion, as detected by an FDA approved test, who have received at least one prior therapy.","The recommended dose is a ramp-up schedule over 5 weeks.  Dosing is initiated at 20 mg for 1 week, followed by 1 week at each dose level of 50 mg, 100 mg, and 200 mg, then the recommended daily dose of 400 mg.",,
172,Vinblastine ,Velban ,Tubulin: microtubule destabilizing,811,1**,mg/m2,IV,bolus,-,0.035,3.45E-08,0.000028,28,0.028,28 ug/L **,0.12,26.2,45 ug•hr/L,45,0.8 L/h/kg,-,98-99%,,1965,"J Pediatr Hematol/Oncol 2006, 28(11): 720",http://www.ncbi.nlm.nih.gov/pubmed/17114958,http://journals.lww.com/jpho-online/pages/articleviewer.aspx?year=2006&issue=11000&article=00004&type=abstract,https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Vinblastine,"Lymphoma: Generalized Hodgkin’s disease, Lymphocytic lymphoma, Histiocytic lymphoma, Mycosis fungoides, Advanced carcinoma of the testis, Kaposi’s sarcoma, Letterer-Siwe disease (histiocytosis X), Choriocarcinoma resistant to other chemotherapeutic agents, Carcinoma of the breast","Pediatric.  **Low dose: label suggests 3.7-11.1 mg/m2, so this is likely to be a very low estimate of clinically achievable Cmax. ",,
173,Vincristine,Vincasar PFS ,Tubulin: microtubule destabilizing,825,1,mg/m2,IV,bolus,-,0.007,6.52E-09,0.0000054,5.4,0.0054,6.52 nM,-,-,-,-,-,-,75%,,1963,"Cancer Res 1981;41:3551-3555; see liposomal formulations;  J Clin Pharmacol 2006, 46(7): 727; see also Cancer Chemother Pharmacol. 1998;41(5):347-52",http://www.ncbi.nlm.nih.gov/pubmed/7260915,http://cancerres.aacrjournals.org/content/41/9_Part_1/3551.long,https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Vincasar,"Leukemia: acute leukemia;  in combination with other oncolytic agents in Hodgkin’s disease, non-Hodgkin’s malignant lymphomas, rhabdomyosarcoma, neuroblastoma, and Wilms’ tumor.",Label suggests 1.5-2 mg/m2 as usual dose,,
174,Vincristine (liposomal),Marqibo,Tubulin: microtubule destabilizing,825,2.25,mg/m2,IV,60 min,q. 7 d,1.479,1.48E-06,0.00122,1220,1.22,1220 ng/ml,-,7.66,14566 ng•hr/ml,14566,345 ml/h,-,75%,,1995,Drug Product Label,n/a,http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/202497s000lbl.pdf,https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Marqibo,"Leukemia: acute lymphoblastic leukemia, Philadelphia chromosome-negative ",,,
175,Vinorelbine,Navelbine,Tubulin: microtubule destabilizing,779,25,mg/m2,IV,20 min,-,0.811,8.11E-07,0.000632,632,0.63,631.9 ng/ml,-,21.4,584.8 ng•hr/mL,585,78 L/h,-,89%,,1994,"Cancer Chemother Pharmacol 2007, 59(3): 407",http://www.ncbi.nlm.nih.gov/pubmed/17051369,http://link.springer.com/article/10.1007%2Fs00280-006-0359-6,https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Vinorelbine,Lung (NSCLC): non small cell lung cancer ,Label recommends up to 30 mg/m2.  Vinorelbine demonstrated high binding to human platelets and lymphocytes; binding to plasma constituents in cancer patients ranged from 79.6% to 91.2%. ,,
176,Vismodegib,Erivedge,Smoothened receptor antagonist/ Hedge Hog inhibitor,421,150,mg,PO,-,q.d.,33.9,3.39E-05,0.014,14282,14,33.9 umol/L,-,96,5240 umol•hr/L,2283446,-,-,>99%,,2012,"Clin Cancer Res 2011, 17(17): 5774",http://www.ncbi.nlm.nih.gov/pubmed/21753154,http://clincancerres.aacrjournals.org/content/17/17/5774.long,https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Vismodegib,"Basal cell carcinoma, metastatic",PK data following 50-57 days of dosing,,
177,Vorinostat  ,Zolinza ,HDAC inhibitor,264,400,mg,PO,-,q.d.,1.2,1.20E-06,0.00032,317,0.32,1.2 uM,1.5,2,4.2 umol•hr/L,1110,3945 ml/min,885 L,71%,1.2 uM,2006,"Drug Product Label; also J Clin Oncol. 2005, 23(17): 3923-31",http://www.ncbi.nlm.nih.gov/pubmed/15897550,http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1855284/,https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Vorinostat,Lymphoma: cutaneous T-cell lymphoma ,"Absorption (AUC) increased approx. 33% by high-fat meal.  I.V. exposure can be 4-15X higher ( 3-10 ug/ml ) see Clin Cancer Res 2003, 9(10): 3578",,
178,Zalcitabine (Dideoxycytidine),Hivid,Nucleoside/Antimetab: Pyrimidine antagonist; reverse transcriptase inhibitor,211,1.5,mg,PO,-,-,0.119,1.19E-07,0.0000252,25,0.025,25.2 ng/ml,0.8,-,72 ng•hr/ml,72,-,0.534 L/kg,<4%,,1992,Drug Product Label,n/a,http://www.accessdata.fda.gov/drugsatfda_docs/label/2002/20199s16lbl.pdf,http://www.accessdata.fda.gov/drugsatfda_docs/label/2002/20199s16lbl.pdf,not approved for cancer indications;  HIV,not approved for cancer indications;  approved for HIV treatment; discontinued 2006; PK from dose recommended for HIV treatment,,
179,Zoledronic Acid  ,Zometa ,Farnesyl Pyrophosphate Synthase Inhibitor,272,4,mg,IV,15 min,-,0.971,9.71E-07,0.000264,264,0.26,264 ng/ml,-,146,420 ng•hr/ml,420,-,-,33-40%,,2001,"J Clin Pharmacol 2002, 42(11): 1228",http://www.ncbi.nlm.nih.gov/pubmed/12412821,http://onlinelibrary.wiley.com/doi/10.1177/009127002762491316/abstract,https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Zometa,Hypercalcemia of malignancy; multiple myeloma;  documented bone metastases from solid tumors,,,
